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Abstract
Primaquine is an important antimalarial drug that is often dose-limited in therapy by
the onset of hemolytic anemia. It is well accepted that this toxicity is due to the action of
its metabolites and not the parent compound. However, the toxic species have not been
identified and little is known about the mechanism underlying primaquine-induced red
cell injury. Previous studies to identify the hemotoxic metabolites have focused on the
redox active phenolic derivatives of primaquine and have shown that a number of these
compounds are capable of decreasing red cell aSH levels and oxidizing oxyhemoglobin
to methemoglobin. However, these derivatives have not been detected in humans
following primaquine administration. Since N-hydroxy metabolites are known to mediate
the hemotoxicity of several other ary lamines, this dissertation addresses the possibility
that an N.. hydroxy metabolite of primaquine may playa role in the hemotoxicity of the
parent compound.
Metabolic studies in rat and human microsomes determined that the known human
primaquine metabolite, 6-methoxy-8-aminoquinoline (6-MAQ) is N-hydroxylated to 6methoxy .. 8.. hydroxylaminoquinoline (MAQ-NOH). MAQ-NOH was shown to be
hemolytic in vivo in rats, and directly hemotoxic in rat erythrocytes. These observations
suggest that primaquine can be metabolized to MAQ-NOH and that this metabolite has
the requisite properties to playa role in the hemotoxicity of the parent compound.
In regard to the mechanism underlying MAQ-NOH hemolytic activity, it was
demonstrated that under hemolytic conditions, MAQ-NOH induced an oxidative stress
within red cells, but the pattern of responses was quite different than other Nhydroxylamines previously shown to have direct hemolytic activity.

xu
In this dissertation, data is presented to suggest that MAQ-NOH may induce
hemolytic injury in the red cell by more than one mechanism; one that involves lipid
peroxidation in the presence of normal amounts of erythrocytic GSH, and one that
involves protein oxidation in red cells with low levels of GSH, as seen in individuals with
glucose-6-phosphate dehydrogenase deficiency. The relative contribution of MAQ-NOH
versus the phenolic type derivatives in mediating this toxicity remains to be assessed.

CHAPTER!
Introduction
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Drug-Induced Hemolytic Anemia

Hemolytic anemia occurs when red blood cells are removed prematurely from the
circulation and the bone marrow is unable to compensate for the loss. It has been a wellrecognized toxic side effect of drugs for many years with the first case reports on the
capacity of phenacetin to induce anemia documented in the 1890's (Cleaves, 1892; West,
1893). While initially the problem of drug-induced hemolytic anemia was given little
attention, it became of great social and military concern during World War II and the
Korean War in response to a high incidence of hemolytic anemia in otherwise healthy
military personnel prophylactically administered primaquine for malaria (Beutler, 1959).
In addition to primaquine, many other compounds are known to induce a hemolytic
response (Beutler, 1959). These include a wide range of structurally and functionally
diverse compounds (Table 1.1) such as the aryl amine drug dapsone, the antibacterial
agent chloramphenicol, and the herbicide propanil. While there does not appear to be any
link in their pharmacological activity that predisposes these compounds to be hemolytic
agents, many of them contain an arylamine nucleus (fig 1.1) or can be metabolically
converted to an aromatic amine in vivo.

Glucose-6-Phosphate Dehydrogenase Deficiency

It was early recognized that hemolytic anemia in response to primaquine was most
pronounced in a particular sub-population of individuals. These include 10-15% of
African Americans (A-) and some Caucasians of Mediterranean descent (Med-), the
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Table 1.1
Compounds Known to Induce Hemolytic Anemia
Analgesics
Acetanilid
Acetylsalicylic acid (*)
Antipyrine
Phenacetin (*)
Pyramidone
Sulfonamides and Sulfones .
Sulfani I ami de
Sulfapyradine
Dapsone
Sulfacetamide
Sulfisoxazole (Gantrisin) (*)
Thiazolsulfone
Sulfoxone (*)
Antimalarials
Primaquine
Pamaquine
Pentaquine
Quinacrine (Atabrine)
Nonsulfonamide Antibacterial Agents
Furazolidone
Nitrofurantoin
Nitrofurazone
Chloramphenicol (***)
Paraaminosalicy lie acid
Miscellaneous
Napthalene
Trinitrotoluene
Methylene Blue (*)
Nalidixic acid
Dimercaprol(*)
Pheny lhydrazine
Quinine (**)
Quinidine(**)
(*) Slightly hemolytic in African Americans, or only in very large doses
(**) Hemolytic in Caucasians, but not in African Americans
(***) Possibly hemolytic in Caucasians, but not in African Americans or Orientals

(from Beutler, 1972)
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Primaquine

OC 2 HS

Phenacetin
NH2

Dapsone

O=~=O

NH2

Acetanilide

Sulfanilamide

Aniline
Fig. 1.1. Structural formulas of various drugs known to induce hemolytic anemia in
humans
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percentage depending on geographical location (Beutler, 1972). This sensitivity was later
associated with an intrinsic genetic defect in the enzyme glucose-6-phophate
dehydrogenase (G6PD). G6PD deficiency is an X-linked recessive trait that affects up to

400 million people worldwide (for review see Beutler, 1990). While it is recognized that
multiple variants of this enzyme deficiency exist, a majority of them result from a single
point mutation that causes an amino acid change in the protein. It is thought that these
mutations occur within the dimer interface of the protein, destabilizing the dimer, and
exposing the monomeric forms to enhanced degradation (Mason, 1996). Thus, the
mutated enzyme has a normal level of activity but a shorter cellular lifespan. Due to the
lack of protein turnover in red cells, G6PD activity is lost as the erythrocyte ages.
Erythrocytes are considered depleted of the enzyme activity after 55 days and 20 days in
A- and Mediterranean varj.ants, respectively.

G6PD is the first enzyme in the hexose monophosphate shunt metabolic pathway and
is solely responsible for generating NADPH in erythrocytes. NADPH is an essential
cofactor for the antioxidant enzyme catalase and the glutathione peroxidase/ reductase
enzyme system (Kirkman and Gaetani, 1984). Therefore, while G6PD-deficient
individuals may not experience any pathology under normal conditions, they are unable
to maintain adequate levels of NADPH and therefore aSH when challenged with an
oxidative stress.
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Malaria
The Disease
In recent literature, malaria was recognized as one of the world's most devastating
human infectious diseases responsible for an estimated 1.5-2.7 million deaths each year,
most of which are children under the age of five (Phillips and Phillips-Howard, 1996;
Miller, 1997). Furthermore, another 300-500 million people are reported to be infected
with the parasite each year and an additional 2.4 billion people are potentially exposed to
the parasite on a daily basis (Phillips and Phillips-Howard, 1996; Miller, 1997). Although
a majority of malaria cases occur in sub-Saharan Africa, it is believed that more than 100
countries throughout Southeast Asia, the Indian subcontinent, the South Pacific region
and Latin America are burdened with this problem (Kondrachine and Trigg, 1997). In
addition, over 1000 cases of malaria per year have been reported in the last decade to the
US Centers for Disease Control; most of these are due to international travelers returning
from endemic areas (Kondrachine and Trigg, 1997; Magill, 1998).

Parasite Life Cycle

Human malarial infections are caused by four species of the plasmodial parasite,
Plasmodiumjalciparum, P. vivax, P. ovale, and P. malariae (Tracy and Webster, 1996).

Individuals primarily contract malaria following a bite from an infected female

Anopheles mosquito. While feeding, the mosquito releases sporozoites from their salivary
glands into the bloodstream of an individual. Once in the bloodstream, the sporozoites are
quickly taken up by the liver and begin the

prim~y

tissue phase of infection. During this
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phase, the sporozoites multiply and develop within hepatocytes into mature tissue
schizonts. After 5-16 days, depending on the species, the schizonts rupture and release
thousands of merozoites into the circulation where they invade red blood cells, initiating
the erythrocytic or blood stage of malaria. Of importance, upon release from the liver, the
parasite is unable to re-infect other tissues. However, in P. vivax and P. ovale infections,
some of the parasites remain in the Ii ver, gi ving rise to the latent tissue form of the
parasite. This form of the parasite is released into the bloodstream at a later date, thus
. causing relapses. Once in the red cell, most of the plasmodia continue to multiply and
develop into schizonts until the red cell ruptures, again releasing merozoites that can
further infect additional erythrocytes. However, some of the parasites will differentiate
sexually within the red cells into gametocytes. It is this form of the parasite that is
ingested by an uninfected mosquito and ultimately develops within the mosquito into a
sporozoite that can infect another individual following the infected mosquito's next blood
meal.

Therapy
The antimalarial drugs in use today are active against different stages of the malaria
parasite (Tracy and Webster, 1996). However, a majority of them are used clinically to
target either the erythrocytic or the tissue forms of the species. For example, both
chloroquine and quinine are known to have gametocidal activity but are primarily used to
kill the asexual blood forms of the parasite. Additional agents active against the blood
forms of malaria include mefloquine and halofantrine. Primaquine is an antimalarial drug
of particular value in that it has been shown to be active against multiple stages of the
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parasite. These include the erythrocytic stages of P. vivax, the primary hepatic forms of

P. jalciparum, and the gametocidal form of all four malaria species (Grewal, 1981;
Peters, 1999). In addition, primaquine is known to be highly effective in treating the
persistent exoerythrocytic, or tissue, form of malaria and therefore is particularly
important clinically for the radical cure of P. vivax and P. ovale infections.

Drug Resistance
The widespread emergence of drug resistant parasites has been the subject of several
recent reviews (Kondrachine and Trigg, 1997; Foley and Tilley, 1998; Milhous and Kyle,
1998). The alarming resurgence

s~en

in malaria cases is thought to be largely due to this

problem. For example, chloroquine resistance has been documented in almost all malaria
endemic areas except Central America (Kondrachine and Trigg, 1997). As this was once
the drug of choice for malaria, its clinical effectiveness has been drastically reduced in
the last 20 years. Furthermore, resistance to the altemati ve sulfadoxine-pyrimethamine is
now rampant in Africa, Southeast Asia and South America (Kondrachine and Trigg,
1997; Milhous and Kyle, 1998). As an alternative course of treatment, infected
individuals are being administered the more expensive antimalarial agents such as
mefioquine, quinine and halofantrine, however, an alarming number of cases of
resistance to these agents are being reported as well (Foley and Tilley, 1998; Milhous and

Kyle, 1998).
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Primaquine

In response to a shortage of the antimalarial agent quinine during World War II, the
US initiated a large research program to develop more effective, safer antimalarial drugs
(Greenwood, 1995). From this program, emerged the 8-aminoquinoline, primaquine,
synthesized by Robert Elderfield (Elderfield et aI., 1955). Extensive use in American
soldiers suffering from relapsing vivax malaria during the Korean War (Garrison et aI.,
1952; Alving et aI., 1953) helped to establish the clinical value of primaquine as the drug
of choice for the radical cure of malaria.
Primaquine continues to be the only drug used clinically today to eliminate the latent
tissue forms of P. vivax and P. ovale infections. Moreover, recently the gametocytocidal
activity of primaquine has been exploited in its co-administration with blood
schizontocidal drugs like chloroquine in an effort to combat the widespread drug
resistance to these agents particularly in P. falciparum infections, the most deadly species
of malaria in humans. (Baird et aI., 1995; Peters, 1999). Of interest, the clinical use of
primaquine has also recently expanded to include treatment of Pneumocystis carinii
pneumonia in patients with acquired immunodeficiency syndrome (Black et aI., 1991;
Toma, 1991; Kantor, 1992).

Mode of Action
Despite its use for more than forty-five years, the therapeutic mode of action of
primaquine is unknown. In particular, it is not understood why primaquine is more
effective against

~he

hepatic stage, than it is against the asexual blood stages of the
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parasite. Furthermore, the

questio~

remains as to whether primaquine anti m.alari al

activity is due to the parent compound or its metaboli tes. One problem facing
investigators in trying to elucidate this mechanism is the lack of a well-developed in vitro
culture system for the latent tissue stages of P. vivax and P. ovale.
While attempts to develop an in vitro culture systems for the human malaria species
have not been successful, two rodent forms, P. yoelii and P. berghei, have been cultured,

in vitro. In this regard, Bates et. al. (Bates et aI., 1990) synthesized a variety of
primaquine analogs and in comparison studies using P. berghei infected HepG2 cells
determined that certain primaquine derivatives were much more potent antimalaria.l
agents than primaquine. These investigators further demonstrated that these derivatives
displayed a linear correlation between spontaneous superoxide formation and antimalarial
activity suggesting that primaquine is converted in the liver to redox active intermediates
that contribute to the parent compound antimalarial activity by inducing an oxidative
stress within the parasite. These data are consistent with previous studies in which redox
active compounds like alloxan, phenylhydrazine, and divicine were shown to sl:lppress
parasitaemia in malaria-infected mice (Clark and Hunt, 1983; Clark et aI., 1984b; Clark et
aI., 1984c).
In contrast, a second group of investigators have proposed that primaquine itself
exerts its antimalarial activity by binding the Plasmodium ubiquinone binding site on
cytochrome b, thereby interrupting the parasite's mitochondrial respiratory chain (Vaidya
et aI., 1993). Specificity has been attributed to the unique structural features of the
parasite ubiquinone-binding site. In support, when tested in vivo in rats infected with P.

yoelii, primaquine induced thickening of the parasite mitochondrial membranes as well as
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dramatic mitochondrial swelling (Boulard et aI., 1983; Bates et aI., 1990) with no effect
on host hepatocyte mitochondria. Although not a hypnozonticidal antimalarial agent,
atovaquinone is known to mediate its activity via this mechanism (Fry and Pudney, 1992;
Srivastava et aI., 1997).

Resistance
There have recently been some reports in the literature of P. vivax resistance to
primaquine treatment in Papua New Guinea, Southeast Asia, and Central and South
America (Krotoski, 1980; Arias and Corredor, 1989; Luzzi et aI., 1992; Bunnag et aI.,
1994; Gascon et aI., 1994; Nayar et aI., 1997). In support of these observations, resistance
has been induced experimentally to the blood schizontocidal activity of primaquine in a
number of malaria species including P. vivax in humans (Arnold et aI., 1961; Thompson,
1967). However, as pointed out by Collins et. ai., (Collins and Jeffery, 1996) these cases

are often in endemic areas that are infested with particularly virulent strains of P. vivax
(Le., Chesson strain from New Guinea) that are known to require higher doses of
primaquine to be eradicated, which suggest that these are cases of tolerance not
resistance. In addition, subsequent examination of many of these reports has determined
that sub-therapeutic dosing, lack of compliance, and re-infection may also contribute to
what appeared to be relapses (Collins and Jeffery, 1996; Looareesuwan et aI., 1997).
As a result of the widespread parasite resistance to many of the blood schizontocides
and possibly to primaquine, it is imperative that new antimalarial agents be developed.
To do so, researchers need to understand the mechanism of action, toxicity, and parasite
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resistance to the existing drugs in order to rationally design more effective drugs with a
higher therapeutic index.

Primaquine Hemotoxicity
Primaquine therapeutic and prophylactic use is limited by its toxic side effects,
methemoglobinemia and hemolytic anemia (Tarlov et aI., 1962; Carson et aI., 1981;
Clyde, 1981). Early clinical studies in G6PD A- deficient individuals characterized the
course of the hemolytic response into three phases: acute, recovery, and resistant phases
(Dern et aI., 1954). During the acute hemolytic phase, up to 50% of the red cells may be
lost from the circulation. A decrease in blood GSH levels, a transient increase in:
methemoglobin levels and the appearance of intraerythrocytic inclusions (Heinz bodies)

have been reported to acc<;lmpany this phase.
Despite continuing primaquine therapy, these patients begin to recover in 7-12 days
following administration of the drug. Beutler and others (Kellermeyer et aI., 1961;
Beutler, 1971) have shown that this self-limiting hemolytic response in A- individuals is
due to the selective destruction of older erythrocytes with decreased G6PD enzyme
activity. As the red cell population becomes enriched in younger cells, the patient
becomes "resistant" to the hemolytic response. Although the surviving cells become
sensitive to primaquine as they age and are removed from circulation, their loss is
compensated for by erythropoiesis. If drug treatment is discontinued, however, fun
susceptibility returns within 4-6 months as the red cells return to the normal pre-drug age
distribution.
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In contrast, the hemolytic response in the Mediterranean variant of G6PD deficiency
is not self-limiting (George et aI., 1967). In Med- individuals the G6PD activity is
markedly decreased in both young and old cells (Piomelli et aI., 1968). Thus a hemolytic
response in these individuals may be much more severe than in an A- variant, perhaps
even life-threatening.

Primaquine Metabolism
It is interesting that despite the importance of metabolism in regard to the mode of
action and toxicity of primaquine (Tarlov et aI., 1962; Fraser and Vesell, 1968; Fletcher
et aI., 1988; Bates et aI., 1990), its metabolic fate remains poorly defined. The chemical
instability of the putative primaquine metabolites, along with their poor recovery from
biological systems has significantly contributed to the difficulty of this problem.(Strother
et aI., 1984; Idowu et aI., 1995). Pharmacokinetic studies of primaquine in humans have
determined that drug bioavailability is 96%, half-life is 6 hours, and volume of
distribution is 250 L indicating extensive uptake into the tissues (Mihaly et aI., 1984;
Mihaly et aI., 1985). Therefore since primaquine is taken chronically (or sub-chronically)
for malaria, the potential exists for drug and/or metabolite accumulation in vivo.
Furthermore, less than 2% of

t~e

administered dose of primaquine is renally excreted

(Mihaly et aI., 1984).
The primary metabolic pathways of primaquine (fig. 1.2) are thought to involve
oxidative metabolism of both the aminoquinoline ring and the alkylamino side-chain of
the molecule (Strother et aI., 1981; Price and Fletcher, 1986; Idowu et aI., 1995).
Primaquine-3' -carboxylic acid (PQ-CX) has been found in the plasma of humans (Mihaly
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et aI., 1984) and rats (Baker et aI., 1982; Clark et aI., 1984a) in significantly higher
concentrations than the parent compound, however, this metabolite was not detected in
the urine, indicating further metabolism prior to excretion. The only other known human
metabolite of primaquine is the N-dealkylated derivative, 6-methoxy-8-aminoquinoline
(6MAQ), which was found in the blood and urine of primaquine treated volunteers (Baty

et aI., 1975).
Two

phenolic

metabolites,

5-hydroxyprimaquine

(5-0H-PQ)

and 6-

desmethylprimaquine (6-DesM-PQ) have been identified in the urine of primaquine
treated dogs (Strother et al., 1981). In addition to these, 5,6-dihydroxyprimaquine
(5,6DHPQ) was detected in the bile of rats during isolated rat Ii ver perfusion studies

(Ward et aI., 1985). In rat liver microsomal studies, using an ethylchloroformate
derivatization technique, Idowu et. al. (Idowu et aI., 1995) identified multiple metabolites
of primaquine including side chain and phenolic oxidation products. However, these
investigators did not detect the major rat primaquine metabolite PQ-CX. Conversely, PQ-

ex was the only metabolite detected in human

liver microsomes (Bangchang et aI.,

1992).

Oxidative Stress in the Red Blood Cell
The ability of hemoglobin to reversibly bind molecular oxygen and carbon dioxide is
essential for tissue oxygenation and removal of carbon dioxide. When bound to
hemoglobin, oxygen is known to e'xist in an equilibrium mixture (fig. 1.3) between
oxyhemoglobin and a superoxide-ferri hemoglobin complex (Wittenberg et aI., 1970).
Formation of this complex is attributed to the capacity of molecular oxygen to acquire
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one of the four unpaired electrons in the outer (d) shell of the heme ferrous iron. When
oxygen is released from hemoglobin, this electron is usually returned to the heme iron.
However, if the electro,n remains With the oxygen during its release from hemoglobin, the
result is the formation of methemoglobin and a superoxide anion radical (Mansouri and
Lurie, 1993). Dissociation of the superoxide-ferri hemoglobin complex occurs constantly
in normal red blood cells, and results in the conversion of up to 0.5% of total body
hemoglobin to methemoglobin per hour (Chiu et aI., 1985).
The red cell contains a number of enzyme systems to cope with the consequences of
this oxidative reaction. Thus methemoglobin is readily reduced back to hemoglobin by a
NADH-dependant redu<;tase (Passon and Hultquist, 1972), and the superoxide is
converted to hydrogen peroxide by superoxide dismutase (Fridovich, 1975). The
hydrogen peroxide, in turn, is detoxified by two enzyme systems, catalase and
glutathione peroxidase/glutathione reductase (Eaton, 1991) as follows:

GSH Red

GSSG

.. 2GSH

Both catalase and glutathione peroxidase/glutathione reductase enzyme systems
require NADPH (Kirkman and Gaetani, 1984). The sole source of this cofactor in the red
cell is the first two steps of the hexose monophosphate shunt pathway, the activity of
which is controlled by a feedback inhibition of the first enzyme in the sequence, G6PD
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by NADPH. Under normal conditions, red cell G6PD is believed to function at less than
3-5% of its maximum capacity (Yoshida and Lin, 1973) and hence the red cell has a
significant reserve capacity to enhance production of this protective

reduc~ant

in the face

of increase in oxidative stress.
That this constant low-level oxidant stress has physiological consequences is well
illustrated by the fact that human red cells that are deficient in G6PD activity have
significantly lower levels of GSH and much shorter life spans (Gaetani et aI., 1979). For
example, the red cells of individuals with the A- type of G6PD deficiency experience a
20% reduction in red cell life span (Harris and Kellermeyer, 1972) .
It has also long been known that a variety of drugs and other environmental chemicals
can enhance the normal level of oxidant stress within the red cell, as indicated by
increased cellular levels of methemoglobin and hydrogen peroxide. Chemicals well
characterized to have this effect include phenylhydrazine (Cohen and Hochstein, 1964;
Goldberg et aI., 1976), menadione (Cohen and Hochstein, 1964; Goldberg et aI., 1976),
and phenylhydroxylamine (Kiese, 1974). More recently, additional active oxygen and
other reactive species have been recognized to be formed under these pro-oxidant
conditions. Thus superoxide, hydroxyl radical, glutathione and hemoglobin thiyl radicals
and ferrylheme have all been detected in red cells exposed to arylhydroxylarnines such as
phenylhydroxylamine and dapsone hydroxylamine (Maples et aI., 1990; Bradshaw et aI.,
1995; Bradshaw et aI., 1997).
Since compounds that enhance oxidant stress within the red cell are hemolytic, and
since red cells that are deficient in their capacity to produce the protective reductant,
NADPH when faced with such an oxidant stress (i.e., G6PD deficient cells), are uniquely
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sensitive to these hemolytic agents, it has long been considered that the hemotoxicity
results from damage to the cell inflicted by these oxidant species. However, precisely
how these reactive species arise and which of them are responsible for the injury, as, well
as the identity of the cellular targets, are still unknown and are the subject of much
ongoing research.
While it is well recognized the superoxide itself is a relatively non-reactive species. in
biological systems (Sawyer and Valentine, 1981), in the presence of hydrogen peroxide,
this radical can lead to the formation of the highly reactive hydroxyl radical via an ironcatalyzed Fenton reaction (McCord and Day, 1978; Halliwell and Gutteridge, 1992). The
hydroxyl radical could further react with cellular sulfhydryl groups to generate thiyl
radicals (Maples et aI., 1990; Bradshaw et aI., 1991; Bradshaw et aI., 1995), any of which
are capable of inducing

oxi~ative

damage to cellular macromolecules, ultimately marking

the red cell for premature removal from the circulation by macrophages of the spleen.
One problem with this scheme is that ferrous iron is required to catalyze the Fenton
reaction, and the ability of hemoglobin to catalyze this reaction is controversial
(Gutteridge, 1986; Puppo and Halliwell, 1988; Dong Mao et aI., 1994). However,
Comporti and colleges have shown that oxidation of hemoglobin to methemoglobin in
red cells treated with hemolytic agents such as phenylhydrazine (Ciccoli et aI., 1994),
divicine (Ferrali et aI., 1992), phenylhydroxylamine, and dapsone hydroxylamine'
(Ciccoli et aI., 1999) resulted in the release of diffusible "redox-active" iron.
In addition to hydroxyl radical generation, hydrogen peroxide is also known to react
with hemoglobin to form the doubly oxidized hemoglobin species, ferrylhemoglobin
(Kanner and Harel, 1985b; Kanner and Harel, 1985a; Harel and Kanner, 1988).
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Perrylhemoglobin (Hb-Fe4 +-OH) is a potent oxidant which has been shown to be capable
of initiating red cell membrane lipid peroxidation (Kanner and Harel, 1985b; Kanner and
Harel, 1985a; Galaris et ai., 1990). In addition, ferrylhemoglobin may also react with
oxyhemoglobin in a comproportionation reaction to form methemoglobin (Giulivi and
Davies, 1990).

HbFe 4+_ OH + HbFe 2+_ 02 -~
.. 2HbFe 3+ + 02
In brief, red cells are well known to be subject to an auto-oxidation that results in the
formation of methemoglobin and hydrogen peroxide. The red cell is well equipped with
oxidant defenses that re-reduce the methemoglobin and detoxify the peroxide. The
hemolytic activity of a variety of arylhydroxylamines and other chemicals has been
associated with an enhancement of this normally low level oxidant stress and is presumed
to result from production of oxidant species at levels andlor rates above the red cells
capacity to remove them. At levels above the protective threshold, additional and more
toxic oxidant species are thought to arise and it is these species which are considered to
be responsible for the cellular injury that causes shortening of the red cell life span by
inducing premature splenic sequestration.

Mechanism of Hemotoxicity
While the mechanism by which hemolytic agents damage red blood cells to the extent
they are removed prematurely from circulation is poorly understood, it is believed that
these agents enhance the process of normal reactive oxygen species formation such that
the antioxidant defenses in the red cell are overwhelmed resulting in an "oxidative stress"
(Beutler, 1959; Tarlov et aI., 1962; Miller and Smith, 1970; Gordon-Smith and White,
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1974; Carrell et aI., 1975). Observations that support this idea include: 1) a decrease in
reduced red blood cell glutathione accompanies a hemolytic episode, 2) hemoglobin
oxidation to methemoglobin and the formation of Heinz bodies (denatured hemoglobin)
following exposure to hemolytic agents, and 3) an enhanced sensitivity to these drugs in
individuals that have a decreased ability to generate adequate levels of NADPH

(i.e~,

G6PD-deficient people) when presented with an oxidative challenge. It was also realized
during these early mechanistic studies that many of these hemolytic agents were not
strong oxidizing or reducing agents and did not induce hemolytic damage when incubated
with red cells in vitro at physiological relevant concentrations (Fraser and Vesell, 1968;
Miller and Smith, 1970; Fletcher et aI., 1988). Thus the concept developed that many of
these hemolytic compounds were metabolized in vivo to more redox active species. that
were responsible for oxidizing critical cellular constituents and initiating the premature
removal of the red cells from circulation (Tarlov et aI., 1962; Fraser and Vesell, 1968;
Beutler, 1971).
In this regard, investigators have examined the possible role primaquine phenolic
derivatives may play in the parent compound toxicity. 5-0H-PQ, 5,6-DHPQ, and 5,6DHAQ, have been shown in vitro to deplete erythrocytic GSH and oxidize
oxyhemoglobin to methemoglobin in both normal and G6PD deficient,red cells (Fraser
and Vesell, 1968; Agarwal et aI., 1988; Fletcher et aI., 1988). It is proposed that these
compounds playa role in primaquine-induced hemotoxicity by redox cycling within the
red cells to their corresponding quinone/ quinone-imine derivatives consequently forming
reactive oxygen species that oxidize critical cellular constituents terminally damaging the
cell (Vasquez-Vivar and Augusto, 1992; Vasquez-Vivar and Augusto, 1994). It is of
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interest that phenolic metabolites of the hemolytic agent aniline were also found to
oxidize hemoglobin in vitro, however, they were not hemolytic in vivo in rats (Harrison
and Jollow, 1986; Harrison and Jollow, 1987). These metabolites although formed in the
liver, are quickly cleared by conjugation reactions and therefore do not contribute to the
parent compound toxicity.
Although it is widely accepted that drug-induced hemolytic anemia results from
oxidati ve damage to the red cells, the mechanism in which these agents impose this
damage is not known. However, some evidence is available to suggest that more than one
mechanism may exist. An elegant study conducted in 1966 on inmates in the Illinois
State Penitentiary (Degowin et al., 1966), illustrated in figure 1.4, demonstrated that
when the hemolytic drug dapsone was administered to G6PD-normal and G6PD-deficient
(A-) volunteers, there was moderate induction of hemolytic anemia in normal individuals
and about a 2-fold increase in sensitivity towards dapsone-induced hemolytic anemia in
G6PD-deficient individuals. In marked contrast, primaquine had little hemolytic activity
in normal individuals, however, A- G6PD deficiency was associated with a 30-fold
increase in sensitivity to primaquine hemotoxicity. While interpretation of the data
remains unclear, it argues strongly for marked variations in the response of red cells to
hemolytic metabolites of these two drugs.

Role of Hydroxylamines in Drug-Induced Hemolytic Anemia
Arylhydroxylamines are known to mediate the hemotoxic side-effects of hemolytic
agents such as aniline, dapsone, propanil, and phenacetin (Harrison and Jollow, 1986;
Grossman and Jollow, 1988; Jensen and lolIow, 1991; McMillan et al., 1991). It is
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believed that these metabolites evoke an oxidative stress within the red cell through a
cyclic oxidation-reduction reaction (fig. 1.5) that involves oxyhemoglobin and molecular
oxygen and yields the nitrosoarene, methemoglobin, and partially redl:lced forms of
oxygen, respectively (Rostorfer and Cormier, 1957; Kiese, 1974). Based on EPR spin
trapping experiments, these reactive oxygen species have been shown to further generate
more reactive hydroxyl radicals and glutathione and hemoglobin thiyl radicals (Maples et
aI., 1990; Bradshaw et aI., 1995; Bradshaw et aI., 1997) that are capable of critically
damaging the red cell. In addition, this reaction is also believed to generate a
phenylnitroxide radical intermediate through the one-electron oxidation of
phenylhydroxylamine (Maples et aI., 1990). The nitrosoarene is subsequently reduced
back to the hydroxylamine by NADPH-dependent reductase and is available to oxidize
another equivalent of hemoglobin. Thus methemoglobin and activated oxygen species are
produced in greater than stoichiometric amounts resulting in an oxidant stress within the
red cell.

Cellular Targets
Although the precise intemallesion that ultimately marks a red cell for sequestration
is not known, four major targets for oxidative attack have been proposed:
1. Hemoglobin. As mentioned previously, several known and putative
primaquine phenolic metabolites including 5-0H-PQ, 5,6-DHPQ, and 5,6HAQ have been shown to oxidize hemoglobin to methemoglobin. It is known
that heme dissociates more readily from methemoglobin (Itano, 1970;
Gutteridge, 1986) after which free globin precipitates easily. Denatured
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hemoglobin is thought to attach to the plasma membrane to form Heinz
bodies (Jacob, 1970). Heinz bodies have been reported to occur in red cells
isolated from primaquine treated patients (Beutler et aI., 1954). The presence
of Heinz bodies may mechanically impede the passage of erythrocytes
through the spleen (Lubin and Desforges, 1972; Weinstein et aI., 1975), alter
the adjacent membrane leading to splenic recognition and sequestration, or
lead to splenic entrapment by inducing spherocyte formation due to splenic
abstracting of the Heinz bodies along with membrane lipids known as a
"pitting" process (Rifkind and Danon, 1965). Alternatively, heme oxidation
may result in the release of iron in a free and diffusible form, which may
catalyze the formation of hydroxyl radicals via the Fenton reaction (Ferrali et
aI., 1992;

Cic~oli

et aI., 1994; Ciccoli et aI., 1999). Hydroxyl radicals are

highly reactive, and can attack a number of intracellular sites, including
membrane lipids and proteins.
2. Sulfhydryl groups. Changes in cellular sulfhydryl status have long been
associated with the premature sequestration of red blood cells. As
demonstrated by Jacob et. al., titration of erythrocyte sulfhydryl groups with
N-ethylmaleimide or p-chloromercuribenzoate causes the cells to be rapidly
taken up by the spleen (Jacob and Jandl, 1962). In addition sulfhydryl
oxidation may promote the formation of mixed disulfides between
hemoglobin and glutathione and between hemoglobin and other cellular
proteins. It has been suggested that these interactions cause a change in the
tertiary/ quaternary structure of hemoglobin facilitating its precipitation to
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A second possible mechanism in which to elicit macrophage ingestion of damaged or
aged erythrocytes includes disruption of the normal membrane phospholipid'
asymmetrical distribution, in particular phosphatidyl serine (PS). Normally PS is
maintained predominantly in the inner leaflet of the plasma membrane by the energy
dependent transporter aminophospholipid translocase (i.e., flippase). Dissipation of the

PS transbilayer gradient has been shown to play an important role in cell-cell recognition
processes including macrophage recognition of apoptotic (Fadok et aI., 1992; Bratton et
aI., 1997) and tumorigenic cells (Conner et aI., 1991; Utsugi et aI., 1991). Of interest, PS
extemalization is also known to drastically enhance macrophage phagocytosis of red
blood cells in vitro (Tanaka and Schroit, 1983; McEvoy et aI., 1986) as well as red cell
clearance in vivo (Schroit et aI., 1985). In addition, aged, sickled, and uremic red cells
(Conner et aI., 1994; Boas et aI., 1998) have been shown to contain PS in their outer
membranes and to bind to macrophages more readily (Tait and Gibson, 1994; Wood et
aI., 1996) than normal erythrocytes. It was hypothesized that PS exposure triggers
macrophage recognition and ingestion of aged or damaged erythrocytes.
Finally, the unmasking of a peptidic antigen that leads to opsonization by circulating
autologous antibodies may signal a red cell for sequestration. A number of studies have
suggested a key role for hemoglobin binding to cytoskeletal proteins in creating this
antigenic site. In this regard, early observations by Morrison et. al. (Morrison et aI., 1983)
of aged red cells included an increase in hemoglobin association with the cell membranes·
prior to their sequestration. Low and colleagues later reported that hemoglobin avidly
binds the cytoplasmic region of the integral membrane protein band 3 and stimulates its
aggregation (Waugh and Low, 1985; Waugh et aI., 1986). In addition, these investigators
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established that clustering of band 3 induced IgG opsonization and subsequent
macrophage ingestion (Low et aI., 1985; Turrini et aI., 1991). These data lead to the
hypothesis that as the red cells age or are damaged, hemoglobin binds to band 3 and
initiates the formation of protein aggregates resulting in the more stable binding of
autologous antibodies. Once a critical density of bound antibody is reached, complement
binds and the cells are recognized by immunoglobulin and complement receptors on the
macrophages and phagocytized.

Rationale and Specific Aims
While metabolites

~f

primaquine have long been known to mediate the parent

compound hemotoxic side effects (Tarlov et aI., 1962; Fraser and Vesell, 1968), the
metabolic profile of primaquine remains poorly defined. The reasons for this are multifactorial beginning with primaquine having a molecular structure with multiple possible
oxidation sites that gives rise to a large number of known and proposed metabolites (fig.
1.2). Moreover, these metabolites are highly unstable in biological systems (Strother et
aI., 1984; Idowu et aI., 1995). Adding to the complexity of this problem, Lee et a1. (Lee et
aI., 1981) have demonstrated substantial species variations in sensitivity towards
primaquine. For example, primaquine hemotoxicity has been particularly difficult to
express in rats after both acute and chronic exposure (Bolchoz unpublished results, Lee et
aI., 1981). Thus classical pharmacokinetic studies to identify potentially hemotoxic
metabolites and determine the relative contribution to primaquine hemotoxicity are
extremely difficult.
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The long-term goal of our laboratory is to understand the mechanism underlyi:ng
primaquine-induced hemolytic anemia. Therefore identification of the potentially
hemotoxic metabolite(s) is crucial. As previous studies have suggested

th~t

drug-indu-ced

hemolytic anemia is mediated by oxidative stress, the experimental approach is to
identify redox active metabolites of primaquine that are potentially hemolytic. We intend
to examine the metabolic formation of these derivatives, determine if they are hemolytic,
and if so, to characterize the "pattern" of damage (i.e., the ratio of lipid to protein
oxidation, change in morphology, effect on cellular sulfhydryl status, nature of radical
formation) induced in rat red cells by these agents under hemolytic conditions.
In addition to facilitating the effort to identify the hemotoxic metabolite(s) of
primaquine, these studies will contribute significantly to the extensive efforts to elucidate
the mechanism of drug-induced hemolytic anemia. In examining the extent to which
these hemolytic agents induce the multiple intracellular lesions mentioned above, we can
begin to assess the significance of these effects in the premature removal of red ceUs
from the circulation.
In contributing to this overall goal, the present studies examine the possible role of 6methoxy-8-hydroxylaminoquinoline (MAQ-NOH) in primaquine-induced hemolytic
anemia. In doing so, we examined MAQ-NOH metabolic formation, hemolytic activity,
and mechanism of inducing hemolytic anemia. The reasons for starting with the Nhydroxy type metabolite are two fold. Previous studies in our laboratory have shown that
the N-hydroxylated metabolites of hemolytic agents such as aniline, dapsone, propanil,
and phenacetin are responsible for the parent compound hemotoxicity (Harrison and
Jollow, 1986; Grossman and Jollow, 1988; Jensen and Jollow, 1991; McMillan et aI..,
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1991). Secondly, 6-methoxy-8-aminoquinoline (6-MAQ), a logical precursor for MAQNOH formation, is one of two known human primaquine metabolites (Baty et aI., 1975).
Thus the following hypothesis and specific aims were developed:

Hypothesis: The primaquine metabolite, MAQ-NOH, induces hemolytic anemia in the
rat by initiating an oxidative stress within the red cell that alters the red cell membrane
integrity.

Specific Aim 1. 1) To establish if 6MAQ is metabolized to MAQ-NOH using rat and
human microsomes. 2) To determine the potency of MAQ-NOH with respect to
hemolytic and methemog1.obinemic activity.

Specific Aim 2. To examine the morphological and oxidative effects of MAQ-NOH in
rat erythrocytes in the presence and absence of aSH focusing on lipid peroxidation and
membrane skeletal protein damage.

Specific Aim 3. To identify the radical species formed in response to MAQ-NOH in rat
erythrocytes under hemolytic conditions.

CHAPTER 2

Primaquine-induced Hemolytic Anemia: Formation and Hemotoxicity of the
Ary lhyroxylamine Metabolite 6-Methoxy -8-hydroxylaminoquinoline
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Introduction

Malaria is considered to be the most widespread parasitic infection in the world, with
nearly one third of the world population threatened by Plasmodium sp. infections (Miller,
1997). Primaquine, an 8-aminoquinoline drug, has been an important antimalarial agent for
over 40 years because of its unique effectiveness against exoerythrocytic forms of the
parasite. Primaquine is currently the only drug capable of treating the persistent liver stages
of P. vivax and P. ovale responsible for relapsing malaria (Tracy and Webster, 1996).
Furthermore, the importance of primaquine has grown recently due to development of
resistance against other antimalarial drugs, and because of its potential for use against
opportunistic Pneumocystis cannni pneumonia in AIDS patients (Kantor, 1992).
Despite its broad antiparasitic activity, primaquine therapy is limited by its capacity to
induce a Heinz-body anemia, particularly in individuals with deficiency in erythrocytic
glucose-6-phosphate dehydrogenase (G6PD) activity (Dem et al., 1955; Degowin et al.,
1966). Deficiency in erythrocytic G6PD has been shown to confer resistance to infection
by the malarial parasite, which presumably accounts for the high incidence of G6PD
deficiency in areas endemic for malaria (Beutler, 1978). Early mechanistic studies
established that 1) primaquine hemotoxicity was due to metabolite(s) of the drug, rather than
the parent compound; 2) glutathione became oxidized to glutathione disulfide and was lost
from the red cell; 3) hemoglobin became denatured and formed large insoluble aggregates
that were attached to the inner surface of the red cell membrane (Le., Heinz bodies); and 4)
the hemolytic activity was associated with an accelerated removal of the damaged (but intact)
red cells from the circulation by the spleen and liver (for review, see Beutler, 1969). The
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identity of the hemotoxic metaboIite(s), however, was not detennined, and the mechanism
underlying the hemolytic response to primaquine remains unknown.
Phenolic metabolites of primaquine have long been suggested as candidate hemotoxic
species (Tarlov et aI., 1962). These oxidation products have been identified as metabolites of
primaquine in the biological fluids of experimental animals (Strother et aI., 1981; Strother et
al., 1984; Idowu et al., 1995), and they have been observed to cause oxidative damage to
nonnal and G6PD-deficient erythrocytes (Strother et al., 1984; Agan.val et al., 1988;
Fletcher et al., 1988). However, phenolic metabolites have not been detected in humans after
administration of primaquine (Baty et al., 1975; Mihaly et al., 1984) or in primaquinetreated human liver microsomes (Bangchang et aI., 1992).
An alternate hypothesis is that the hemotoxicity of primaquine is associated, in part or in
whole, with an arylhydroxylamine metabolite. Primaquine is known to undergo Ndealkylation in humans to yield 6-methoxy-8-aminoquinoline (6-MAQ) (Baty et al., 1975).
In previous studies with other arylamines, such as aniline and dapsone, we have observed
that their N-hydroxy metabolites are direct-acting hemotoxicants and are responsible for the
hemolytic activity of the parent compounds (Harrison and Jollow, 1986; Grossman and
JoBow, 1988). It is thus plausible that 6-MAQ could be converted to its N-hydroxy analog
(fig. 2.1), and that this metabolite could be capable of inducing methemoglobinemia and
hemolytic damage.
To investigate whether an arylhydroxylamine metabolite could be involved In
primaquine hemotoxicity, we have synthesized the putative N-hydroxy metabolite, 6methoxy-8-hydroxylaminoquinoline (MAQ-NOH), and have examined the capacity of rat
and human liver microsomes to form this metabolite. In addition, we have assessed the
ability of MAQ-NOH to induce methemoglobin formation and hemolytic damage in rat
erythrocytes. We report that MAQ-NOH was fonned in both rat and human liver
mi cro somes , and that MAQ-NOH is a direct-acting methemoglobinemic and hemolytic

agent in rats. These results suggest that N-dealkylation of primaquine followed by N-
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obtained (fig. 2.2) with chemical shifts (in ppm referenced to the solvent) at 3.86 (s, 3H, 6OCH3), 6.92 (d, 1=2.5 Hz, IH, Hs), 6.96 (d, 1=2.5 Hz, IH, H7), 7.74 (dd, 1=4.8 Hz,1=8.4

Hz, IH, H3), 8.59 (d, 1=8.4 Hz, IH, 14), 8.77 (dd, 1=1.5 Hz, 1=4.7 Hz, 1H, H2); the 8amino protons were not observed.
MAQ-NOH was synthesized as previously described (Allahyari et al., 1984). Breifly,
40 mg of platinum oxide in 13.33 ml of ethyl acetate was reduced for in a Parr
hydrogenator for 5 min under 12 psi of hydrogen. Next, 4 grams of 6-methoxy-8nitroquinoline in 93.3 ml of ethyl acetate was added to a suspension and reduced for 1 hour
at 31 psi. The reaction was cooled in the freezer overnight and the precipitate was
recrystallized once from acetone. HPLC analysis of the product showed <1 % residual 6methoxy-8-nitroquinoline. Mass spectral analysis (fig. 2.3) revealed a molecular ion (M+)
at mlz 191, and a predominant fragment ion at mlz 175. MSIMS analysis of the M+
revealed fragment ions at mlz 176 (M+ -15), 173 (M+ -18), and 162 (M+ -29). The NMR
spectrum of MAQ-NOH (fig. 2.4) showed chemical shifts at 3.84 (s, 3H, 6-0CH3), 6.69

(d, 1=2.7 Hz, IH, H5), 6.76 (d, 1=2.7 Hz, IH, H7), 7.43(dd, 1=4.2 Hz, 1=8.3 Hz, IH, H3),
8.13 (dd, 1=1.6 Hz, 1=8.3 Hz, IH, R4), 8.56 (dd, 1=1.7 Hz, 1=4.2 Hz, IH, H2), 8.67 (s, IH,
-NH), 8.79 (8, IH, -NOH). DQ-COSY analysis of the cross peaks confirmed the
assignment of the aromatic ring protons. The synthetic compounds were stable under argon
at-80°C.

HPLC Analysis
Chromatography was performed on a Waters HPLC system (Waters Assoc., Milford,
MA) consisting of a Model 6000A pump, a Rheodyne injector (20 JlI loop) and a 250 rom
Altech Platinum EPS CI8 reverse,..phase column. 6-MAQ was eluted with 35% acetonitrile
in water at a flow rate of 1.2 m1Imin, and was detected on a Waters model 481 IN-Vis
variable wavelength detector set at 280 nm. MAQ-NOH was eluted with 40% methanol in
water containing 0.1 % trifluoroacetic acid and 10 mM ammonium acetate at a flow rate of

6- 0CH 3

2

3
5

4

H7--'
.-H5
H2
DMSO
H3
H4

I
9

8

7

6

5

Fig. 2.2. NMR spectrum of synthetic 6-MAQ

4

3

2

I

I
ppm

~

o

41

(A)
205.2

100 -

I

-

-'o;:!(

80

_I

( ])

I

co

-,I

c

1

i

"'0
C
::::J

co
(])

---.

1

()

.0

Oxidation Product
(MAQ-N0 2)

60

I

-!,

>

:.;::

co

(])

a::

175.3

[M+Hr
159.1
160.3

I

I

I

I

1

iii

i

,..
I I

191 .0
I

i

I

I
I

I ....

i

I

I

Iii

i

I ,
I I

ii

170

160

I .. I

..
i

i

i

I

Iii

I

I

I

i

I
j

206.3

'T· ..
I

I i

I

I I I
I i

I.
i

ii

190

180

i

,

I

I

III

,

I

II· .
L

ii

i

210

200

m/z

(8)

190.2

100 - I

191.3

-';:!(
0

80

(])
()

I

C

-I

co

"'0
C

1

::::J

.0
~
(])

1

'192.2

60 -

.~
......

co

- I

(])

i

a::

162.2

40 -

20

173.0

159.9

'I

I

II
I

160

172.2
I

I

170

I

176.9
I

I

I

180

I

I

190

I

I

200

m/z

Fig. 2.3. (A) ESI mass spectrum of synthetic MAQ-NOH. (B) ESI MSIMS
of the parent ion (mlz 191).

210

6-0C H 3
1

N~2
3

s

4

H7-+

DMSO

.-HS
H2

H4

H3

-NH
-NOH

\

\
I
9

8

7

6

5

4

3

r

2

I
ppm

Fig. 2.4. NMR spectrum of synthetic MAQ-NOH
~

N

43
1.5 mUrnin, and was detected using either 1) a Bioanalytical Systems (West Lafayette, IN)
LC-4B electrochemical detector equipped with a glassy carbon working electrode (oxidation
mode, +0.35 volts) and a Ag/AgCI reference electrode; or 2) a Waters Millennium model
996 photodiode array detector.

NMR Spectroscopy and Mass Spectrometry
Mass spectral analysis was performed on a Finnigan LCQ Quadrapole ion trap tandem
mass spectrometer. The instrument was operated in positive-ion mode with electrospray
io~zation

(ESI) needle voltage, 4.2 kV; ESI capillary temperature, 200

o

e;

isolation width, 2

amu; scan range 100-500 amu. MSIMS data was simultaneously acquired for the selected
parent ion (mlz 191). Helium was used to fragment the ion with a collision parameter set to
35. Proton NMR spectra were acquired on a Varian VXR 400 spectrometer operating at 400
MHz with conventional quadrature detection.

Microsomal metabolism of6-MAQ
6-MAQ (1 mM) was incubated with male Sprague-Dawley rat and pooled human liver
microsomes (1.0 mg proteinlml) in 100 mM phosphate buffer pH 7.4. The reaction was
initiated by the addition of an NADPH generating system (163 J.tM B-NADP+, 1.7 mMglucose-6-phosphate, and 0.375 U glucose-6-phosphate dehydrogenase). The incubation
was conducted in a shaking water bath at 37°C. Aliquots (100 JLl) were removed at 1, 3,,5,
10, 20, and 30 min, added to 100 J.tl of cold methanol and centrifuged at 13,500 x g for 1
min. An aliquot of the supernatant (20 J.tl) was then injected immediately into the HPLC for
analysis. The concentration of MAQ-NOH in the microsomal incubations was quantified
by measuring the peak height against a standard curve obtained by addition of synthetic
MAQ-NOH to microsomal protein.
To obtain a mass spectrum of the microsomal metabolite, three microsomal suspensions
(1 ml) were concentrated using Oasis lll..B 1 cc CI8 Extraction Cartridges (Waters Assoc.,
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Milford, MA). The cartridges were washed with 1 ml of methanol and equilibrated with 1 ml
of water. After loading the microsomal incubation on the cartridge, it was washed with 5%
methanol/water. The metabolite was eluted with 1 m1 of 100% methanol and dried in a
Speed Vac Concentrator. The three samples were then pooled and dissolved in 750/0
methanol/water, and injected onto the HPLC. The peak corresponding to the metabolite was
collected, and an aliquot was injected directly into the ion source of the mass spectrometer
for analysis.

Hemotoxicity Studies
The level of methemoglobin in erythrocyte suspensions treated with MAQ-NOH (100-

2,500 JIM) was measured as described previously (Harrison and Jollow, 1987). Briefly, 100

Jll aliquots of the red cell suspensions were added to 5 ml of hemolysis buffer (0.277%
potassium phosphate monobasic, 0.289% sodium phosphate dibasic, and 0.05% Triton X100; pH7.8). The hemolyzed solution was divided into four 1 ml aliquots; 20 JlI of 10%
KeN was added to the second and forth aliquots, and 20 Jll of 20% KFe(CN)6 was added
to the third and forth aliquots. The absorbance of each aliquot was detennined at 635 nm.
The percent methemoglobin of total hemoglobin was calculated as %methemoglobin =
(A 1-A2)/( A3- A4» 100.

The survival of 51Cr-labeled red cells was detennined in vivo after in vitro exposure to
various concentrations of MAQ-NOH (0-750 JLM) as described previously (Harrison and
Jollow, 1986). Briefly, MAQ-NOH dissolved in DMSO (10 JII) was added to erythrocyte
suspensions (40% red cells, 2.0 ml) and allowed to incubate aerobically for 2 hr at 37°C.
After the incubation, the red cells were washed once, resuspended in PBSG, and 0.5 rn1
aliquots were administered intravenously to isologous rats. Thirty minutes after
administration of the labeled red cells a TO blood sample was taken from the orbital sinus,
and then serial samples were taken at 48 hr intervals for 14 days. At the end of the
experiment, the radioactivity in the blood samples was counted concurrently in a well-type
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gamma counter, and the counts above background were expressed as percentage of the To
sample. The time for blood radioactivity to decrease to 50% of initial levels (51CrT50) was
determined for each animal by regression analysis. Statistical significance was detennined
with the use of Student's t-test.
To detennine the hemolytic activity of MAQ-NOH in vivo, untreated 51Cr-Iabeled red
cells were administered intravenously to isologous rats. A TO blood sample was taken via
the orbital sinus 48 hr after administration of the labeled cells. MAQ-NOH (150 and 250
mg/kg, i.p.) dissolved in DMSO (0.5 ml/kg, i.p.) was administered immediately after the TO
blood sample was taken. Serial blood samples were taken at the designated intervals and
assayed as described above for the in vitro incubation/in vivo survival protocol.

Results

Microsomal Metabolism of6-MAQ
To determine whether an N-hydroxy metabolite of 6-MAQ could be formed by rat and
human liver microsomes, 6-MAQ (1 mM) was incubated with liver microsomes (1 mglml)
containing an NADPH-generating system for 3 min at 37°C. At the end of the incubation
period, an aliquot (100 JlI) was removed, added to ice-cold methanol (100 JLI) and
centrifuged. An aliquot of the supernatent (20 JlI) was then injected immediately onto the
HPLC-EC. As shown in fig. 2.5C, a single chromatographic peak was observed from the rat
microsomal sample. This peak was not observed in the absence of an NADPH-generating
system (fig. 2.5B). The retention time of the metabolite peak was identical to that of
synthetic MAQ-NOH (fig. 2.5A), and its UV-visible absorbance spectrum also was
identical (data not shown). Formation of the metabolite was time dependent, being linear for
about 3-5 minutes (fig 2.6A).
To confirm the identity of the microsomal metabolite, rat microsomal incubations were
analyzed by ESI mass spectrometry. To generate a sufficient amount of the metabolite for
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MS analysis, three separate microsomal incubations were canied out with 6-MAQ (0.1
mM) for 10 min, and then the reaction mixtures were pooled and subjected to solid-phase

extraction. The extract was concentrated in a Speed Vac, injected onto the HPLC, and the
metabolite peak was collected and injected into the mass spectrometer. The mass spectrum
of the metabolite (fig. 2.7 A) showed a molecular ion at mlz 191, consistent with the addition
of an hydroxyl group on 6-MAQ. A fragment ion at mlz 175 (M+-16, -0) was also
observed, indicating the loss of elemental oxygen from the molecular ion. This loss of 16

mlz units has been observed previously with other N-hydroxyarylamine compounds (Lay
et. aI., 1986). The molecular ion (mlz 191) was then selected and subjected to ESI MS/MS.
The MSIMS spectrum of the microsomal metabolite (fig. 2.7B) showed three fragment ions
at mlz 176 (-15; -CH3), 173 (-18; -H20), and 162 (-29; -CHO). This fragmentation
pattern was also seen in the MSIMS of synthetic MAQ-NOH.
Incubation of 6-MAQ with human microsomes in the presence of NADPH (fig. 2.5D)
resulted in the fonnation of a metabolite with the same retention time and UV spectrum as
that of the rat (fig. 2.5C). The fonnation of MAQ-NOH by human microsomes was linear
for about 5 minutes (fig. 2.6A). Of interest, the extent of fonnation of MAQ-NOH by
human microsomes was about twice that of rat microsomes.
Parallel stability studies, in which a known amount of MAQ-NOH was added to rat
microsomal suspensions, indicated that MAQ-NOH disappeared in an apparent first-order
manner with a Tl/2 of about 6 minutes (fig. 2.6B). Thus it is likely that the observed
production of MAQ-NOH in rat and human microsomal suspensions is an underestimation
of the enzymatic capacity of the microsomes to N-oxidize 6-MAQ.

In vivo hemolytic activity of MAQ-NOH

To examine the hemolytic potential of MAQ-NOH in vivo, groups of rats were infused
with 51Cr-Iabeled erythrocytes 48 hr before i.p. administration of various doses of MAQNOH (dissolved in DMSO) or the vehicle alone. After an initial blood sample (To), serial
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blood samples were obtained to allow detennination of the time necessary for the
radioactivity to decline to 50% of the To value (51Cr-Tso) for each animal. As shown in fig.
2.8, vehicle-treated controls exhibited a gradual decline in blood radioactivity (51Cr-Tso of

9.27 ± 0.34 days) that is considered to reflect primarily the normal removal of senescent
erythrocytes. Erythrocyte survival after administration of a 150 mglkg (0.94 mmol/kg) dose
ofMAQ-NOH was not significantly different from controls. However, the 250 mglkg (1.57
rnmol/kg) dose produced a statistically significant increase in the rate of removal of the
radiolabeled erythrocytes (51Cr-T50 ~f 6.36 + 1.1 days). Unfortunately, administration of
higher doses of MAQ-NOH (>300 mglkg) were lethal due to acute respiratory depression,
which precluded the construction of a complete dose-response curve for MAQ-NOH
hemolytic activity in vivo.

Direct Hemotoxicity of MAQ-NOH
To detennine if MAQ-NOH acts directly upon red cells to produce hemolytic damage,
rat Sler-Iabeled erythrocytes were resuspended in PBSG (40% hematocrit) and incubated
with various concentrations of MAQ-NOH in vitro for 2 hr at 37°C. No evidence for
hemolysis was observed under these incubation conditions. The cells were then washed
once, administered intravenously to isologous rats, and serial blood samples were taken for
15 days. As shown in fig. 2.9A, exposure of the labeled cells to MAQ-NOH induced a
concentration-dependent increase in the rate of removal of radioacti vity from the blood as
compared to controls. The concentration-dependence of this response is shown in fig. 2.9B;
the hemolytic response is plotted as the percentage reduction in the 51Cr-T50 of the
experimental animals relative to the mean control value. The EC50 under these experimental
conditions was about 350 jLM. In contrast to MAQ-NOH, treatment of 5 1er-Iabeled
erythrocytes with 6-MAQ (1.5 mM) did not increase significantly the rate of removal of
radioactivity from the blood as compared to control,S (data not shown).
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To examine the capacity of MAQ-NOH to induce methemoglobinemia in vitro, the
time- and concentration-dependence of methemoglobin fOITIlation was examined in rat
erythrocyte suspensions exposed to MAQ-NOH. As shown in fig. 2.10A, incubation of
erythrocyte suspensions with MAQ-NOH (750 JLM) resulted in the rapid fonnation of
methemoglobin. Methemoglobin levels reached a peak of about 250/0 within an hour af
MAQ-NOH exposure, and then declined gradually over the next 2 hrs. In contrast, the level
of methemoglobin in control incubates remained low and constant during the course of the
experiment. The MAQ-NOH concentration dependence of this response after 60 min· of
incubation is shown in fig. 2.7B. Methemoglobin levels under these conditions ranged from
about 100/0 methemoglobin at 100 JLM MAQ-NOH up to about 65% methemoglobin at 2.5
mMMAQ-NOH.

Discussion
The present results demonstrate that 6-MAQ, a known human metabolite of primaquine,.
can be N-hydroxylated to form MAQ-NOH by both rat and human liver microsomes (fig.

2.5e and D). Incubation of rat red cells with this metabolite caused a concentration...
dependent formation of methemoglobin (fig. 2.10B). When 51er-tagged red cells were.
incubated with MAQ-NOH, washed, and then administered to isologous rats, survival of the
tagged red cells in the circulation was reduced in a concentration-dependent manner. Under
the incubation conditions chosen (aerobic for 2 hr at 37°C in buffer containing glucose)" no
evidence for frank hemolysis was observed, and the EC50 for the hemolytic response was
about 350 JLM MAQ-NOH (fig. 2.9B). Furthermore, MAQ-NOH was able to provoke a
hemolytic response when administered directly to rats (fig. 2.8).
Although the crucial role of metabolism in primaquine hemotoxicity has been accepted
for over 40 years (Fraser and Vesell, 1968), the hemotoxic metabolite(s) have not been
identified. Lack of progress is due in large part to the multiplicity of the known and
proposed pathways of primaquine metabolism (fig. 1.2), all of which can give rise to
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metabolites with redox potential. Moreover, poor organic solubility and instability of these
putative metabolites have complicated their extraction and quantification from biological
media (Idowu et al., 1995). These obstacles, combined with the difficulty in provoking a
hemolytic response in laboratory animals with primaquine (Lee et aI., 1981; Jollow et aI.,
unpublished studies), have hampered efforts to determine the contribution each metabolite
makes towards methemoglobin formation and hemolytic damage in vivo.
To overcome these problems, investigators have synthesized phenolic derivatives of
primaquine and have examined their effects in erythrocyte suspensions. Following the
suggestion of Tarlov and colleagues (Tarlovet aI., 1962), much attention has been given to
the 5-hydroxy- and 5,6-dihydroxy metabolites of primaquine (fig. 1.2), which (via 5,6quinone formation) could support redox cycling and the generation of active oxygen species
(Link et al., 1985). In support of this postulate, these compounds were shown to induce a
variety of oxidative effects in both normal and G6PD-deficient red cells, including
stimulation of hexose monophosphate shunt activity (Baird et al., 1986), hemoglobin
oxidation and GSH depletion (Strother et al., 1981; Agruwal et al., 1988; Fletcher et al.,
1988). More recently, Vasquez-Vivar and Augusto (1994) showed that a 500 JLM
concentration of the quinoneimine derivatives of these metabolites (prepared by treatment of
the phenols with hydrogen peroxide) could induce oxidative damage and increase the
osmotic fragility of rat erythrocytes. When examined under the same experimental
conditions, 6-MAQ was found by these investigators to be inactive. Thus, they concluded
that phenolic metabolites were the toxic species and that an N-hydroxylated metabolite was
unlikely to contribute to the hemotoxicity of primaquine. However, MAQ-NOH was not
synthesized in these studies and tested directly, and it is not clear that sufficient levels of
MAQ-NOH could have been generated from 6-MAQ under their experimental conditions
to allow adequate test of the postulated role of this metabolite. Moreover, since hemolytic
anemia in humans is associated with sequestration of intact red cells rather than with

intravascular hemolysis (Rifkind, 1966), the relevance of their observed increases in osmotic
fragility is uncertain.
While the in vivo survival data in fig. 2.9 clearly indicates that MAQ-NOH is directly
hemolytic to G6PD-nonnal rat red cells, these data do not allow for direct assessment of the
role of MAQ-NOH in primaquine hemotoxicity. It is noteworthy, however, that the pattern
of the response produced by MAQ-NOH exposure; i.e., the rate of Sler uptake with no
evidence of frank lysis, was similar to that observed with arylhydroxylamine metabolites of
aniline and dapsone. The type of damage inflicted by these direct-acting hemolytic agents
has been shown to be consistent with an acceleration of the normal removal of "aged" but
intact red cells from the circulation by the spleen (Jollow and McMillan, 1998). The
hemolytic potency of MAQ-NOH (ECso 350 JlM) towards G6PD-normal rat red cells, as
measured in the in vitro/in vivo assay, was about 2-fold lower than that of dapsone
hydroxylamine (ECso ca. 150 JlM) which mediates the hemolytic activity of dapsone
(Grossman and Jollow, 1988), and about three-fold more potent than N-hydroxyphenetidine
(EC50 ca. 900 p,M), which mediates the hemotoxicity of phenacetin (Jensen and Jonow,

1991).
The in vitro exposure/in vivo erythrocyte survival assay allows the hemolytic damage
observed in vivo to be reproduced in vitro under controlled conditions during a 2-hr
incubation period before the cells are returned to the circulation of isologous rats, and thus
is a useful indicator of relative hemolytic potency among direct-acting hemolytic agents.
However, this assay cannot be utilized to define the MAQ-NOH blood concentrations
needed to cause a hemolytic response in vivo. Previous studies with dapsone hydroxylamine
have demonstrated that hemolytic activity is proportional to the AVe of the metabolite and
is not dependent on its concentration (Grossman and Jollow, 1988). Since the half-life of
primaquine in humans is about 6 hours (Fletcher et al., 1981), it is likely that 6-MAQ and
the secondary metabolite, MAQ-NOH, will be produced at a low but steady rate during
chronic primaquine therapy. Thus, while the concentration of MAQ-NOH in the circulation
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may never be very high, its AVe may be appreciable and reach toxicologically significant
levels in G6PD-deficient patients.
Assessment of the contribution that MAQ-NOH makes to primaquine hemotoxicity is
further complicated by the probability that the putative phenolic metabolites discussed above
are fonned in humans and hence also have the potential to induce hemolytic injury. In
preliminary studies using the in vitro exposurelin vivo erythrocyte survival assay, we have
observed that both 5-hydroxyprimaquine and 5-hydroxy-6-desmethylprimaquine are directacting hemolytic agents with hemolytic potencies similar to that of MAQ-NOH
(unpublished results).' Thus, primaquine could be metabolized to three types of hemotoxic
species: phenolic, diphenolic and arylhydroxylamine, each of which would be capable of
undergoing redox cycling within the red cell. 5-Hydroxyprimaquine forms a redox pair with
its p-quinoneimine analog, the 5,6-diphenolic metabolite with either an o-quinone or a pquinoneimine, and the 8-hydroxylamino metabolite (i.e., MAQ-NOH) with its nitroso
analog. These considerations emphasize the need for more detailed studies on the
metabolism of primaquine in rats and humans, and raise the possibility that more than one
type of metabolite is responsible for primaquine hemotoxicity.
In the present studies on the metabolism of 6-MAQ, we did not detect a phenolic
metabolite in either rat or human microsomal incubations. This does not indicate that these
metabolites are not fanned, but does raise the possibility that either they may not be major
contributors to the hemotoxicity of 6-MAQ, or that their instability is much greater than that
of MAQ-NOH under these experimental conditions. Further experiments will be necessary
to determine whether phenolic metabolites of primaquine can be detected in humans. In
addition, the effect of CYF inducers and inhibitors on the metabolism of primaquine and 6MAQ will be necessary to identify' CYP isoforms responsible for toxic vs. non-toxic
pathways, and will be crucial in the development of a primaquine-sensitive animal model.
In regard to the mechanism underlying primaquine-induced hemolytic anemia, data
published by Degowin et al. (1966) first raised' the possibility that oxidative damage to

58
erythrocytes could anse by different mechanisms depending -on the oxidant. These
investigators reported that the doses of primaquine necessary to evoke signs of hemolysis in
A- G6PD-deficient volunteers are about 20-fold lower than those required to elicit a similar

response in G6PD-normal volunteers, whereas the doses of dapsone required to induce
similar responses in G6PD-deficient vs. normal differ only by a factor of two. Although the
underlying basis for these differences is not clear, it may

b~

explained by the fact that

dapsone hemotoxicity is mediated solely by N-hydroxy metabolites, whereas primaquine
hemotoxicity could be mediated by multiple hemotoxic species, quinone, quinoneimine, and
arylhydroxylamine (fig. 1.2). Clearly, a quantitative assessment of the contribution each
type of metabolite makes towards the hemotoxic response will be important in elucidating
the mechanism underlying primaquine-induced hemolytic anemia.
In summary, we have demonstrated that a known hUn;J.an metabolite of primaquine, 6MAQ, can be N-hydroxylated by both rat and human liver microsomes, and that this Nhydroxy metabolite is hemolytic in vivo in rats, and is directly hemotoxic to the rat red blood
cell. The contribution of this metabolite to primaquine hemotoxicity remains to be assessed.

CHAPTER 3
Primaquine-Induced Hemolytic Anemia: Effect 6-Methoxy-8Hydroxylaminoquinoline on Rat Erythrocyte Sulfhydryl Status, Membrane Lipids,
Cytoskeletal Proteins and Morphology
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Introduction

The antimalarial drug primaquine has been the drug of choice for the treatment of the
exoerythrocytic forms of Plasmodium vivax and P. ovale for more than 40 years (Tracy
and Webster, 1996). Recently, primaquine has also been utilized for its gametocytocidal
activity against P. Jalciparium to help combat widespread drug resistance of this species
to blood schizonticides, such as chloroquine (Peters, 1999). Furthermore, primaquine is
used to treat mild to moderate cases of Pneumocystis cannni pneumonia in patients with
acquired

immunode~iciency

syndrome (Toma et aI., 1998). Despite the clinical

importance of primaquine, its therapeutic use is limited by its toxic side-effects,
hemolytic anemia and methemoglobinemia (Dern et aI., 1955; Degowin et aI., 1966).
The mechanism by which primaquine induces hemolytic anemia remains elusive.
Early mechanistic studies established that: 1) metabolite(s) of primaquine are the toxic
species; 2) GSH is lost from the red cell prior to a hemolytic response; 3) denatured
hemoglobin aggregates (i.e., Heinz bodies) are associated with the red cell membrane;
and 4) hemolytic anemia is particularly pronounced in individuals who are deficient in
glucose-6-phosphate dehydrogenase (G6PD) activity (for review, see Beutler, 1969).
Collectively, these observations led to the concept that primaquine-induced hemolytic
anemia is caused by oxidati ve stress. However, the identity of the toxic primaquine
metabolites and the nature of the oxidant stress are not known.
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We have reported recently that the known human primaquine metabolite, 6-methoxy-

8-aminoquinoline (6-MAQ), can be N-hydroxylated to form 6-methoxy-8hydroxylaminoquinoline (MAQ-NOH) by both rat and human microsomes (Bolchoz et

aI., 2001). Furthermore, MAQ-NOH was found to be a direct-acting hemolytic agent in
the rat; that is, when rat 51Cr-Iabeled red cells are incubated with MAQ-NOH in vitro and
returned to isologous rats, the labeled red cells are more rapidly removed from the
circulation than are the vehicle-treated control cells.
Although sequestration of senescent or damaged (but intact) red cells from the
circulation is known to occur by macrophages of the reticuloendothelial system (Rifkind,
1966), the signal that marks these cells for removal remains unknown and continues to be
a subject for debate (for review, see Bratosin et aI., 1998), One group of studies suggests
that peroxidative damage ,to the plasma membrane lipid bilayer transmits the signal for
sequestration (Lubin and Chiu, 1982; Zwaal and Schroit, 1997). Alternatively, membrane
skeletal protein alterations may underlie the removal process. For example, alteration in
the lateral distribution of band 3 protein via hemoglobin (or hemichrome) binding has
been shown to result in the binding of autologous antibodies, which commit the cells for
uptake by cultured monocytes (Waugh et aI., 1987; Turrini et aI., 1991).
In view of the critical role proposed for oxidant damage in the mechanism underlying
primaquine-induced hemolytic anemia, we have examined the effect of MAQ-NOH on
sulfhydryl status, membrane lipids and skeletal proteins in suspensions of rat erythrocytes
using MAQ-NOH concentrations known to induce the premature removal of these cells
from the circulation. We report that MAQ-NOH has only a modest capacity to oxidize
red cell GSH to GSSG and as-protein mixed disulfides, and to induce the formation of
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hemoglobin-skeletal protein adducts. In contrast to other arylhydroxylamines, exposure
of normal rat red cells to MAQ-NOH significantly enhanced the peroxidation of
membrane lipids. When aSH was depleted from rat red cells to mimic the low levels of
aSH that are observed in the human G6PD-deficient red cell (Gaetani et al., 1979), the
hemolytic activity of MAQ-NOH was markedly enhanced. This exacerbation was
associated with the development of protein thiol oxidation without change in the level of
lipid peroxidation. It is suggested that MAQ-NOH can inflict hemolytic injury on the red
cell by two pathways; lipid peroxidation in GSH-normal red cells and protein oxidation
in GSH-depleted red cells. The possibility of synergistic interaction between these
processes and among the hemotoxic metabolites of primaquine is discussed.

Materials and Methods
Chemicals and Materials
MAQ-NOH was synthesized as described previously (Allahyari et al., 1984).
Malondialdehyde, diethyl maleate (DEM), and rabbit anti-rat hemoglobin IgG were
purchased from Sigma Chemical Co. (St Louis, MO). HRP-conjugated donkey anti-rabbit
IgG was purchased from Amersham Pharmacia (Piscataway, NJ). Na251Cr04 in sterile
saline (1 mCi/ml, pH 8) was obtained from New England Nuclear (Billerica, MA). All
other chemicals were of the best commercially available grade.
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Animals

Male Sprague-Dawley rats (75-100 g) were purchased from Harlan Laboratories
(Indianapolis, IN) and were maintained on food and water ad libitum. Animals were
acclimated to a 12-hr light-dark cycle prior to their use.

Red Cell Incubation Conditions

Blood from the descending aorta of anesthetized rats was collected into heparinized
tubes and washed in isotonic phosphate-buffered saline (pH 7.4) supplemented with 10
mM D-glucose (PBSG). After removal of the plasma, the red cells were resuspended in

PBSG to a 40% hematocrit and used the same day they were collected. Experiments were
carried out by addition of various concentrations of MAQ-NOH dissolved in DMSO (lO
ttl) to the erythrocyte suspensions (2 ml) and allowed to incubate at 37°C for up to 2 hr.

Detennination of Sulfhydryl Status

GSH content was determined as described previously (Grossman et aI., 1992).
Aliquots (0.2 ml) of the incubation mixtures were lysed with 800 Jd of cold EDTA (1
mM) and the protein precipitated with 500 pJ of 25% sulfosalicylic acid. Following a 5

min incubation on ice, the protein was pelleted at 10,000 rpm for 2 min. To assay for

GSH, 500 JlI of the supernatant was added to 1 ml of Tris-acetate buffer (0.5 M; pH 7.6)
and 2 ml of phosphoric acid (1 M). GSH content was analyzed by HPLC with
electrochemical detection as described below.
To detennine GSSG, 500 JlI of supernatant was added to 1 ml of Tris-acetate buffer
(0.5 M; pH 7.6) and 10 Jll of n-octanol. The mixture was incubated with sodium
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borohydride (50 mg) at 37°C for 30 min. After incubation, the mixture was chilled, 2 ml
of phosphoric acid (1M) was added, and GSH content analyzed.
To determine GS-protein mixed-disulfides the protein pellet was washed with 25%
sulfosalicylic acid, suspended in a solution containing 2.970 m! of 25% sulfosalicylic
acid, 15 JLl Triton X-100, and 15 III Antifoam, homogenized for 30 sec in a Polytron
homogenizer (Brinkman), and centrifuged at 15,000 rpm for 10 min. The pellet was
treated with sodium borohydride (50 mg), homogenized for 30 sec, and incubated at 37°C
for 30 min. After incubation, the mixture was chilled, treated with 2 ml of phosphoric
acid (1M), centrifuged at 15,000 rpm for 10 min, and the content of solubilized GSH
detennined.
GSH content was determined by HPLC with electrochemical detection.
Chromatography was performed on a Waters HPLC system (Waters Assoc., Milford,
MA) consisting of a Model 6000A pump, a Rheodyne injector (10 Jllioop) and a 3.9 x
150 mm Waters Nova Pak C8 column. GSH was eluted with 8% methanol in 50 mM
potassium phosphate buffer (pH 2.4) containing 5 mM heptane sulfonic acid with a flow
rate of 1.2 mllmin and detected on a Bioanalytical Systems (West Lafayette, IN) LC-4B
electrochemical detector equipped with a AulHg amalgam electrode operating at +100 V.
The amount of sulfhydryl present in the samples was determined by comparison of peak
heights to standards prepared identically to the samples.

Morphological Examination of Red Cells
After incubation, red cells treated with the vehicle (DMSO) or MAQ-NOH were
washed and prepared for scanning electron microscopy as previously described
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(Grossman et aI., 1992). The red cells (1 ml aliquots) were fixed in 0.1 M cacodylate
buffer containing 1% glutaraldehyde and 2% formalin for 20 min. The cells were affixed'
onto O.2-JLm filters using a Swinney connector attached to a syringe. The cells were fixed
an additional 40 min as above, washed in saline, and dehydrated in a graded series of
ethanol solutions ranging from 50-100% ethanoL The cells were then dried by critical
point drying, cast with a thin coat of carbon and gold, and examined in a JEOL JSM5410LV scanning electron microscope operating at 10 kV accelerating voltage and no
tilt.

Preperation of Red Cell Ghosts

Red cell ghosts were prepared from vehicle- and MAQ-NOH-treated red cells as
described previously (Grossman et aI., 1992). After incubation, washed red cells w'ere
lysed in 20 ml of phosphate buffer (5 mM, pH 8.0) containing 20 mg of
phenylmethylsulfonylfluride and centrifuged at 13,500 rpm for 10 min. The supernatant
was removed by aspiration. The ghosts were washed extensively in phosphate buffer (3-4
washes) to remove any unbound hemoglobin. Red cell ghosts were also prepared from
red cells treated with dapsone hydroxylamine (DDS-NOH), and were used as a positive
control for the presence of hemoglobin-skeletal protein adducts (Grossman et aI., 1992).

Detennination of Lipid Peroxidation in Red Cells

Red cells were analyzed for thiobarbituric acid-reactive substances (TBARS) as
previously described (McMillan et aI., 1998). Following a 60 min incubation in the
presence of MAQ:NOH, aliquots (900 JlI) of the suspension were added to 76.5 JLI of
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trichloroacetic acid to precipitate

~he

proteins and centrifuged at 13,000 x g for 2 nUn.

The supernatants (600 pJ) were incubated with thiobarbituric acid (600 pJ 0.67% in
water) at 100°C for 15 min. After the samples cooled to room temperature, their
absorbance was read at 532 nm. TBARS was quantitated based on a standard

cu~ve

generated with known amounts of malondialdehyde prepared identically to the samples.
Statistical significance was determined with the use of the Student's T-test.
Lipid peroxidation was also ~ssessed by measuring the level of F2-isoprostanes in red
cell ghosts prepared from MAQ-NOH-treated red cells as described previously (Morrow
and Roberts, 1999). Membrane phospholipids were extracted from the red cell ghosts and
subjected to alkaline hydrolysis to release esterified F2-isoprostanes. Free F2-isoprostanes
were converted to pentafluorobenzyl ester trimethylsilylether derivatives and measured
by GCIMS. F 2-isoprostanes were quantitated based on a standard curve generated with
known amounts of the F2-isoprostane eH4]8-iso-PGF2a •

Electrophoretic Analysis of Membrane Skeletal Proteins

Red cell ghosts (100 JLI) were solubilized in 40.6 JLI solubilization buffer (7% SDS,
35% glycerol, 25 mM EDTA, 0.28 M Tris-base). Aliquots (containing 35 JLg of protein)
were resolved on non-reducing, continuous gels consisting of 5% monomer and 1.5% bisacrylamide crossli,nker as described by McMillan et. aI.. (McMillan et aI., 1995). The
resolved proteins were either stained with Gel Code Blue (Pierce,' Rockford, IL) or
transferred to PVDF membranes according to the method of Towbin et. al. (Towbin et
aI., 1979). The skeletal proteins were resolved Protein bands were identified according to
their migration distance (Fairbanks et aI., 1971).
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Blotted proteins were blocked in TBST (Tris-buffered saline containing 0.5% Tween20, pH 7.5) containing 5% w/v non-fat dry milk at 27°C overnight, washed 3 times,in
TBST and incubated in TBST containing 0.1 % bovin serum albumin (fraction V) and
primary antibody (diluted 1:10,000) at room temperature for 1 hr. The blotted proteins
were washed 3 times in TBST containing 5% w/v non-fat dry milk and incubated with
the peroxidase-conjugated secondary antibody at room temperature for 1 hr. Blots were
developed with EeL detection system (Amersham Phannacia Biotech, Piscataway, NJ).

GSH Depletion of Red Cell Suspensions
DEM dissolved in acetone was added to packed red cells at an initial concentration of
0.121 ttl/ml packed cells. After a 15 min incubation at 37°C the red cells were analyzed
for aSH content by HPLC with electrochemical detection as described above. This
treatment typically reduced aSH concentrations to about 5-10% of the initial level, and
this level of depletion was maintained throughout the course of the experiment. The cells
were then resuspended in PBSG (40% suspension) and used on the same day that they
were collected.

Detennination afthe Hemolytic Response
The survival of 51er-Iabeled red cells in vivo after in vitro exposure to MAQ-NO'H
was determined as described previously (Harrison and Jollow, 1986). After the
incubation, the red cells were washed, resuspended (40% hematocrit), and an aliquot (0.5
ml) was administered i.v. to isologous rats. To blood salnples were taken from the orbital
sinus 30 min after the administration of the labeled cells. Additional samples were taken
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in 48 hr intervals for 14 days. At the end of the experiment the samples were counted in a
well-type gamma counter, and the data were expressed as a percentage of the TO blood
sample. Each data point represents four rats.

Results

Effect of MAQ-NOH on Rat Erythrocyte Sulfhydryl Status

It has been shown that GSH levels are decreased in G6PD-deficient individuals given
primaquine (Tarlov et aI., 1962; Beutler, 1969). Thus, the effect MAQ-NOH on GSH
levels was examined in rat erythrocytes in vitro under previously established hemolytic
conditions (Bolchoz et aI., 2001). MAQ-NOH was added to rat red cell suspensions, and
aliquots were taken at various time points and analyzed for aSH, ossa and OS-protein
mixed disulfides by HPLC . As shown in fig. 3.1A, addition of a TCso concentration of
MAQ-NOH (350 JlM) to rat red cells resulted in a transient decline of aSH to about 70%
of initial levels, reaching a nadir within 30 min. The loss of aSH was matched by an
increase in both OSSG and OS-protein mixed disulfides.
Examination of the concentration dependence of the effect of MAQ-NOH on
erythrocyte GSH levels indicated that the pattern of the response was unchanged over the
range of 350-1000 J,tM. When the nadir of aSH content (at 30 min) was plotted against
MAQ-NOH concentration (fig. 3.1B), the ECso of GSH depletion by MAQ-NOH was
estimated to be about 1000 JLM. Of interest, this concentration-response curve for MAQNOH-induced GSH oxidation is shifted significantly to the right of the concentration-
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Fig. 3.1. (A) Effect of MAQ-NOH on rat erythrocyte sulfhydryl status. Rat erythrocytes
were incubated at 37°C in PBSG containing MAQ-NOH (350 11M). At the indicated time
points aliquots were withdrawn and assayed for GSH, GSSG, and GS-protein mixed
disulfides. The values shown are means + SD (n=3). (B) Concentration response
relationship for GSH oxidation by MAQ-NOH in rat erythrocytes. Percent reduction in
GSH was detennined using the nadir values (30 min) for GSH as compared to controls.
Values are means of duplicate determinations.
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response curve previously reported for MAQ-NOH hemolytic activity (TC50 ca. 350 JLM)
(Bolchoz et aI., 2001).

Effect of MAQ-NOH on Rat Erythrocyte Membrane Lipids

To determine whether lipid peroxidation could be detected in rat red cell suspensions
exposed to MAQ-NOH, TBARS formation was measured after a 60 min incubation with
MAQ-NOH. As shown in fig. 3.2A, the amount of TBARS formed in MAQ-NOH-treated
red cells was increased significantly as compared to the vehicle-treated control cells.
TBARS formation was dependent on MAQ-NOH concentration up to 350 p,M.
Although TBARS is a widely accepted method for the measurement of lipid
peroxidation, problems with the specificity of this assay are well known (Moore and
Roberts, 1998). Thus, F2-isoprostane content in MAQ-NOH-treated red cell ghosts was
used to confirm the induction of lipid peroxidation. Following a 2-hr incubation with
various concentrations of MAQ-NOH, the cells were washed and lysed in hypotonic
saline to prepare red cell ghosts. Esterified isoprostanes were hydrolyzed and extracted,
and the content of free F2-isoprostanes in the sample was quantified by GC/MS. As
shown in fig. 3.2B, MAQ-NOH induced a concentration-dependent increase in the
formation of F2-isoprostanes, which confirmed the results obtained with the TBARS
assay.

Effect of MAQ-NOH on Rat Erythrocyte Membrane Skeletal Proteins

Membrane skeletal proteins from control, DDS-NOH (included as a positive control)
and MAQ-NOH-treated red cells were separated on SDS-PAGE gels and either stained
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Fig. 3.2. (A) Formation of TBARS in rat erythrocytes exposed in vitro to MAQ-NOH.
Rat erythrocytes were incubated at 37°C for 60 min in PBSG containing the indicated
concentrations of .MAQ-NOH. Control cells were incubated in PBSG containing the
vehicle (10 JLI DMSO). After the incubation, the cells were lysed, centrifuged and
analyzed for TBARS as described in "Materials and Methods". The values are means +
SD (p< 0.05, n=5). (BY Formation of F2-isoprostanes in ghosts prepared from rat
erythrocytes exposed in vitro to MAQ-NOH. Erythrocyte suspensions (40% RCT) were
incubated with the indicated concentrations of MAQ-NOH for 2 hrs at 37°C. After
incubation, erythrocyte ghosts were prepared and analyzed for F2-isoprostane content as
described in "Materials and Methods". The values are means + SD (n=4). *Significantly
different from control (p< 0.05).

72

with Gel Code Blue or transferred to PVDF membranes and immunostained with antihemoglobin polyclonal antibodies. As shown in fig. 3.3A, the electrophoretic pattern of
membrane skeletal proteins of the positive control (DDS-NOH, lanes 6-7) showed the
characteristic changes previously described (Grossman et aI., 1992); viz., broadening of .
protein bands 1 and 2, loss of bands 2.1 and 4.2, splitting of band 3, and the formation of
hemoglobin aggregates. Immunoblot analysis using the anti-hemoglobin antibody (fig.
3.3B) confirmed that the changes in electrophoretic mobility were due to formation of

hemoglobin adducts with the skeletal proteins, and of the presence of monomeric and
polymeric forms of hemoglobin.
MAQ-NOH-treated red cells (fig. 3.3A, lanes 2-5) were not significantly different
from the control (lane 1) in regard to the mobility of the skeletal proteins. The absence of
significant levels of skeletal protein-hemoglobin adducts was confirmed by the antihemoglobin immunoblot (fig. 3.3B, lanes 2-5). Of interest, a concentration-dependent
increase in the amount of hemoglobin monomer (16 kDa) was observed in the Gel Code
Blue-stained gel, as well as in the anti-hemoglobin immunoblot (fig. 3.3B, lanes 2-5).

Effect of MAQ-NOH on Rat Erythrocyte Morphology

To investigate the effect of MAQ-NOH on rat erythrocyte morphology, red cell
suspensions were incubated in the presence and absence of MAQ-NOH, and aliquots of
the cells were prepared for scanning electron microscopy. As shown in fig. 3.4A, red
cells treated with the vehicle (10 JLI DMSO in 2 ml red cell suspension) for 2 hr at 37°C
retained their nonnal biconcave appearance, though occasional small protuberances were
observed in some of the cells. These protuberances were not seen in cells incubated in
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Fig. 3.3. Effect of MAQ-NOH on rat erythrocyte membrane skeletal proteins. Rat
erythrocytes were incubated for 2 hr at 37·C in the presence of the vehicle (lane 1), 150
JlM (lane 2), 350 tLM (lane 3), 750 tLM (lane 4), and 1.0 mM (lane 5) MAQ-NOH and
130 JlM (lane 6) and 250 tLM (lane 7) DDS-NOH. The cells were washed and membrane
ghost were prepared and washed extensively to remove the unbound hemoglobin. The
ghosts (32 tLg protein) were the solubilized in SDS and subjected to PAGE. A) Gel Code
blue stained gel and densitometric scans; B) immunoblot stained with rabbit anti-rat
hemoglobin. The protein bands were identified according to Fairbanks et al. (1971).
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(A)

(8)

Fig. 3.4. Effect of MAQ-NOH on rat erythrocyte morphology. Scanning electron
micrograph of (A) rat erythrocytes incubated for 2 hrs at 37°C in PBSG containing the
vehicle; and (B) rat erythrocytes exposed to MAQ-NOH (lmM). Magnification X2000.,
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normal saline alone and are attributed to the DMSO. Rat erythrocytes incubated with
MAQ-NOH, even at a very high concentration (1 mM; fig. 3.4B), also exhibited normal
discocytic morphology.

Effect of MAQ-NOH on GSH-Depleted Erythrocytes
The enhanced sensitivity of red cells from G6PD-deficient individuals to the
oxidative actions of certain drugs is considered to be due to their diminished capacity to
maintain sufficient levels of NADPH, and hence GSH, when challenged by the oxidant
stress. In an effort to reproduce this enhanced sensitivity in normal rat red cells, GSH was
depleted by >90% using DEM prior to MAQ-NOH exposure. As shown in fig. 3.5, the
hemolytic activity of MAQ-NOH (250 JLM) was increased markedly in GSH-deficient
red cells (T50 = 0.85 ± ,0.06 days) as compared to MAQ-NOH-treated red cells with
normal GSH levels (T50 = 7.4 ± 0.6 days). Survival of red cells treated with DEM alone
(T50

= 8.6 ± 0.8 days) was not significantly different from the controls (Tso = 9.5 + 0.9

days). As shown in Table 3.1, GSH depletion did not increase the extent of lipid
peroxidation (TBARS formation) in MAQ-NOH treated red cells, indicating that the
enhanced toxicity was not due to exacerbation of lipid peroxidation.
SDS-PAGE analysis of the skeletal proteins (fig. 3.6A) revealed an increase in
hemoglobin monomer present in aSH-deficient red cells treated with MAQ-NOH (lanes
2-4) as compared to the GSH-norrnal MAQ-NOH control (lane 1). Immunoblot analysis
using an anti-hemoglobin antibody (fig. 3.6B) showed that in the GSH-depleted cells,
MAQ-NOH also caused a concentration-dependent increase in the formation of
hemoglobin adducts with the membrane skeletal proteins (spectrin, ankyrin, bands 3 and
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Fig. 3.6. Effect of MAQ-NOH on the membrane skeletal proteins of GSH-depleted
erythrocytes. GSH depleted (90%) nit erythrocytes were incubated in the presence of
DMSO (lane 1), 150JlM MAQ-NOH (lane 2), 250jlM MAQ-NOH (lane 3), or 350JLM
MAQ-NOH (lane 4) for 2 hr at 37°C. Following exposure, the cells were washed and
membrane ghosts were prepared and washed extensively to remove any unbound
hemoglobin. The ghosts (32Jlg of protein) were solubilized in SDS and subjected to
PAGE. A) Gel Code Blue stained gel B) immunoblot stained with rabbit anti-rat
hemoglobin. The proteins were identified according to Fairbanks et al. (1971).
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4.2). The increase in membrane-bound hemoglobin was observed in the form of high
molecular weight aggregates (> 100 kDa) and in hemoglobin monomers and dimers (lanes
2-4). These data indicate that in aSH-deficient red cells, skeletal protein becomes a
preferential target of the oxidant action induced by MAQ-NOH.

Discussion

The present results demonstrate that under in vitro incubation conditions known to
commit rat erythrocytes to premature removal from the circulation after their readministration to isologous animals, MAQ-NOH induced alterations in red cell
sulfhydryl status (fig. 3.1) and caused damage to the plasma membrane in the form of
lipid peroxidation (fig. 3.2). Overall, the data presented here support the concept that
oxidative stress underlies MAQ-NOH hemolytic activity.
On the one hand, the ability of MAQ-NOH to deplete GSH was not unexpected in
view of our previous studies with other arylhydroxylamines, and as with these other
agents, the loss of GSH could be accounted for by oxidation to GSSG and as-protein.
However, examination of the time-course (fig. 3.1A) and concentration dependence (fig.
3.1B) for MAQ-NOH-induced alterations in sulfhydryl status indicated that there are
striking differences between this compound and previously examined N-hydroxy
compounds. For example, with DDS-NOH, hemolytic activity is associated with a rapid,
extensive and long-lasting depletion of red cell aSH (Grossman et aI., 1992). In the case
of MAQ-NOH, the loss of aSH was transient and relatively modest across the full range
of hemolytic concentrations. These data indicate that the MAQ-NOH concentrationresponse curve for GSH oxidation (ECso ca. 1000 JlM) is well to the right of the curve
for the hemolytic response, which has a TCso of about 350 JlM and exhibits a maximal
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response at about 750 JLM (Bolchoz et aI., 2001). This relationship suggests that while
MAQ-NOH does cause depletion of red cell aSH, the depletion of cellular aSH per se is
not a prerequisite for the oxidative stress-mediated hemolytic damage that MAQ-NOH
inflicts on the red cell.
On the other hand, MAQ-NOH-induced lipid peroxidation was unexpected in view of
the lack of lipid peroxidation observed previously in red cells treated with hemolytic
concentrations of DDS-NOH (McMillan et aI., 1998). Lipid peroxidation was detected in
MAQ-NOH-treated red cells using two independent measurements, TBARS and F2isoprostanes (fig. 3.2), and occurred across the range of hemolytic concentrations of
MAQ-NOH. In contrast,. cytoskeletal protein thiol oxidation, as indicated by formation of
hemoglobin-skeletal protein adducts, was not significant after exposure of red cells to
hemolytic concentrations of MAQ-NOH (fig. 3.3). These data suggested that skeletal
protein is not the preferred intracellular target of MAQ-NOH, as it is for DDS-NOH.
It should be noted that although skeletal protein was apparently not affected by
MAQ-NOH, there was a concentration-dependent increase in the amount of hemoglobin
monomer present in membrane ghosts prepared from MAQ-NOH-treated red cells (fig.
3.3). This monomer could not be removed from the ghosts by repetitive washing and is
presumed to be bound either non-covalently (hydrophobic interaction) or covalently to
the lipid matrix. The molecular form of this membrane-bound hemoglobin and its
significance remain to be determined. Nevertheless, binding of the monomer may be a
key event in the hemolytic process because it is observed with other arylhydroxylamines,
such as DDS-NOH (Grossman et aI., 1992), and has been seen with other hemolytic
agents, such as divicine (McMillan et aI., 2001), as well as in rat red cells aged to
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senescence by the serial hypertransfusion technique (McMillan and Jollow, unpublished
observations ).
Alterations in erythrocyte morphology were notably absent in MAQ-NOH treated red
cells (fig. 3.4). In view of the well known role of the skeletal protein assembly in the
maintenance of red cell shape (Marchesi, 1985), the lack of gross morphological changes
in these red cells is consistent with the absence of changes in the electrophoretic mobility
of the skeletal proteins on SDS-PAGE gels (figs. 3.3 and 3.6). The lack of morphological
change after hemolytic concentrations of MAQ-NOH is in sharp contrast to the dramatic
changes in erythrocyte morphology observed with other hemolytic agents. For example,
hemolytic concentrations of DDS-NOH and divicine induce distinctive echinocytic
morphology (Grossman et aI., 1992; McMillan et aI., 2001), and phenylhydrazine is well
known to cause transformation of red cells to spheroechinocytes (Rifkind and Danon,
1965).
Although the data presented here support an oxidative stress-type mechanism for
MAQ-NOH hemotoxicity, its low potency as a GSH-depleting agent made us wonder
whether cells lacking GSH (or the ability to replenish it) would be more sensitive to
MAQ-NOH induced oxidant damage. Furthermore, we reasoned that since lipid
peroxidation appeared causal in the hemolytic process whereas protein oxidation was not,
then any enhancement in hemotoxicity provoked by depletion of GSH should be .
accompanied by corresponding increases in lipid peroxidation without affecting the level
of protein oxidation. When red cell GSH was depleted (>90%) by titration with DEM
prior to exposure to MAQ-NOH, the hemolytic activity of MAQ-NOH was markedly
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enhanced (fig. 3.5). Surprisingly, however, exacerbation of hemolytic activity was not
accompanied by an increase in lipid peroxidation (Table 3.1).
Although the SDS-PAGE pattern of the skeletal proteins was not visibly changed in
MAQ-NOH-treated, GSH-deficient red cells (fig. 3.6A), examination of the skeletal
proteins by immunoblotting revealed the presence of hemoglobin-skeletal protein
adducts. Moreover, the presence of these adducts in GSH-deficient red cells was
dependent on MAQ-NOH concentration (fig. 3.6B). The fact that the amount of
hemoglobin adducted to the skeletal protein was insufficient to perturb the SDS-PAGE
pattern suggests that it is quantitatively much less than that seen with equally hemotoxic
concentrations of a "pure" protein thiol oxidizer, such as DDS-NOH. This raises the
possibility that protein oxidation and lipid peroxidation act additively, and perhaps even
synergistically, in

initia~ing

the intracellular events that lead to premature splenic

sequestration. However, it should be noted that the quantitative relationship between the
initial "hit" and commitment of the cells to removal is not yet known. The possibility that
MAQ-NOH may operate by multiple mechanisms in the aSH-depleted red cell, and that
these mechanisms may be synergistic, is intriguing and warrants further investigation.
We have shown previously that N-hydroxylamines are responsible for the hemolytic
acti vity observed after administration of several arylamine drugs and environmental
chemicals, including aniline (Harrison and J ollow, 1986), dapsone (Grossman and
Jollow, 1988), phenacetin (Jensen and JoBow, 1991) and propanil (McMillan et aI.,
1991). Although the mechanism by which these N-hydroxylamines cause hemolytic
injury is not completely understood, evidence suggests that these compounds produce
damage within red cells as a consequence of their coupled oxidation with
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oxyhemoglobin, yielding methemoglobin and the arylnitroso derivative. In the course of
this reaction, reactive oxygen species, thiyl radicals and possibly other (i.e., compoundcentered) free radicals are generated (Kiese, 1974; Maples et aI., 1990; Bradshaw et aI.,
1997). It is believed that these free radicals oxidize critical sites within the red cell that
ultimately transmit a signal to the external cell surface, marking the cell for removal from
circulation by macrophages. The precise internal lesion responsible for premature
sequestration of these cells, whether on lipid or protein, is still not known.
One theory is that free radical induced membrane lipid peroxidation may playa role
in transmitting a signal for removal. Jain et al. (Jain, 1984) have shown that the lipid
peroxidation byproduct malondialdehyde can flip phosphatidyl serine from the inner to
the outer leaflet of the plasma membrane. Disruption of the asymmetrical distribution of
phosphatidyl serine in the plasma membrane has been shown to stimulate
erythrophagocytosis (Tanaka and Schroit, 1983; McEvoy et aI., 1986; Bonomini et aI.,
2001). A second postulate suggests that disulfide-linked hemoglobin adducts to critical
membrane skeletal proteins, formed via hemoglobin thiyl radical attack of the protein
free sulfhydryl groups, initiates red cell sequestration (Jollow et aI., 1995; Jollow and
McMillan, 1998). In support of this postulate, a number of investigators have shown that
hemoglobin attachment to the cytosolic domain of band 3 causes alterations in the lateral
distribution of this integral membrane protein leading to the binding of autologous
antibodies on the external cell surface, which initiates erythrophagocytosis (Lutz et aI.,
1984; Waugh et aI., 1986; Waugh et aI., 1987; Turrini et aI., 1991).
In conclusion, assessment of the contribution that MAQ-NOH makes towards the
hemotoxicity of primaquine is difficult. One problem is the multiplicity of unstable,
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redox-active metabolites that are formed during the metabolic clearance of primaquine.

These include several phenolic derivatives that have been implicated by others in the
hemotoxicity of primaquine (Link et aI., 1985; Augusto et aI., 1988; Fletcher et aI., 1988;
Agarwal et aI., 1991). Thus, it is conceivable that primaquine hemotoxicity in humans is
mediated by more than one type of toxic metabolite.
Secondly, there may be interactions among these metabolites which facilitate the
development of oxidative damage within the erythrocyte. For example, preliminary
observations in our laboratory indicate that a phenolic metabolite, 5-hydroxyprimaquine,
is also a direct-acting hemolytic agent. Furthermore, in contrast to MAQ-NOH, 5hydroxyprimaquine is also a potent GSH-depleting agent (McMillan et aI., unpublished
studies). This observation suggests that by depleting GSH, 5-hydroxyprimaquine may
sensitize the red cell to the hemolytic activity of MAQ-NOH. If so, this effect would be
amplified in G6PD-deficient red cells due to their already reduced levels of aSH. As
noted by Degowin et al. (Degowin et aI., 1966), G6PD-deficient individuals are about 2030 fold more sensitive to the hemolytic activity of primaquine than are G6PD-normal
individuals. Clearly, the possibility of metabolite synergism in primaquine-induced
hemolytic anemia warrants further investigation.

CHAPTER 4
Primaquine-Induced Hemolytic Anemia: Formation of Free Radicals in Rat
Erythrocytes Exposed to 6-Methoxy-8-Hydroxylaminoquinoline
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Introduction

Hemolytic anemia and methemoglobinemia are well recognized dose-limiting side
effects in the therapeutic use of arylamine drugs, such as primaquine and dapsone
(Beutler, 1969). Because these compounds are not hemotoxic when incubated with red
cells in vitro, it has long been appreciated that metabolites are responsible for onset of the
hemolytic response. In the cases of aniline (Harrison and Jollow, 1986), dapsone
(Grossman and Jollow, 1988), and phenacetin (Jensen and JolIow, 1991), we have shown
that the hemolytic metabolites are their N-hydroxy derivatives. Primaquine metabolism,
on the other hand, is relatively more complex and the metabolites which mediate the
hemotoxic responses have not been identified. A variety of known and putative phenolic
metabolites of primaquine are redox-active and therefore have the potential to mediate
primaquine hemotoxicity (Strother et aI., 1984; Baird et aI., 1986; Fletcher et aI., 1988;
Agarwal et aI., 1991); however, direct evidence for their hemolytic activity is lacking.
We have recently explored an alternative hypothesis; that primaquine hemotoxicity is
mediated by an N-hydroxylated metabolite, 6 methoxy-8-aminoquinoline (MAQ-NOH).
Although the mechanism underlying the damage and removal red cells by hemolytic
N-hydroxylamines remains unclear, oxidative stress has long been considered to playa
prominent role in the process (for review, see Beutler, 1971). This concept is based on the
well-known association of hemotoxicity with oxidation of erythrocytic GSH (to GSSG
and glutathione-protein mixed-disulfides), methemoglobin formation, and with
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enhanced sensitivity to the hemolytic effect of these agents in individuals deficient in
glucose-6-phosphate dehydrogenase (G6PD) activity.
Considerable evidence generated by Kiese and colleagues (Kiese, 1974) suggests. that
the oxidative stress provoked by N-hydroxylamines is due to a cyclic oxidation-reduction
reaction involving the hydroxylamine, oxyhemoglobin, and molecular oxygen, to yield
the nitrosoarene, methemoglobin, and partially reduced forms of oxygen, respectively.
This interaction has been shown to produce greater than stoichiometric amounts, of
reactive oxygen species (i.e., hydrogen peroxide, superoxide anion radical, hydroxyl
radical) and sulfur-centered free radicals (i.e., glutathione and hemoglobin thiyl radicals),
and thus has long been considered to generate reactive species capable of causing cellular
injury (Rostorfer and .Cormier, 1957; Maples et ai., 1990; Bradshaw et aI., 1995;
Bradshaw et aI., 1997).
We have reported recently that an N-hydroxy metabolite of primaquine, MAQ-NOH,
is a direct-acting hemolytic agent in rats, and hence may be a contributor to primaqui,neinduced hemolytic anemia (Bolchoz et aI., 2001). Although the hemolytic response
induced by this metabolite was generally similar to that of other structurally related
hydroxylamines, we observed some marked differences in the· oxidative activity of this
metabolite in rat red cells (Bolchoz et aI., 2002). Of interest, when hemolytic
concentrations of MAQ-NOH were added to rat red cells, the depletion of cellular aSH
and the formation of methemoglobin was significantly less than that seen with equally
hemolytic concentrations of other arylhydroxylamines, implying a quantitative difference
in the extent of oxidant stress and cellular injury. Furthermore, this metabolite induced
concentration dependent lipid peroxidation without evidence of protein oxidation.
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However, when red cell aSH was depleted by titration with diethyl maleate prior to
MAQ-NOH exposure, there was a marked enhancement of hemolytic activity without a
corresponding increase in lipid peroxidation. The enhanced hemotoxicity was
accompanied instead by the appearance of protein oxidation in the form of disulfidelinked hemoglobin-skeletal protein adducts. We have hypothesized that free radicals,
derived either from molecular oxygen or MAQ-NOH itself (i.e., a compound-centered
free radical), are responsible for the damage to membrane lipids and skeletal proteins that
marks the injured red cells for premature removal from the circulation by macrophages in
the spleen.
Thus, the present studies were conducted to determine if free radicals could be
detected and identified in rat red cell suspensions exposed to hemolytic concentrations of
MAQ-NOH, and thus have a role in MAQ-NOH-induced hemolytic injury. MAQ-NOH
was added to rat red cell suspensions, and the incubates were analyzed by UV-visible
spectroscopy and EPR using the spin trap 2-ethoxycarbonyl-2-methyl-3,4-dihydro-2Hpyrrole-l-oxide (EMPO). We report that MAQ-NOH was able to generate hydroxyl
radicals and ferryl heme species under hemolytic conditions. Furthermore, formation of
the hydroxyl radical was constant for twenty minutes and dependent on the presence of
erythrocytic aSH. These data support the concept that oxygen free radicals are involved
in the process underlying MAQ-NOH-induced hemolytic damage

Materials and Methods
Chemicals
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Diethylenetriaminepentaacetic acid (DTPA) and diethyl maleate were obtained from
Sigma Chemical Co. (St. Louis, MO). EMPO was purchased from Oxis Research.
(Portland OR). MAQ-NOH was synthesized as described previously (Allahyari et aI.,
1984). All other reagents were of the best commercially available grade.

Animals

Male Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN) and
were maintained on food and water ad libitum. Animals were acclimated to a 12-hour
light-dark cycle for one week prior to their use. Blood was collected from the descending
aorta of anesthetized rats into heparinized tubes and washed three times in isotonic
phosphate-buffered saline (pH 7.4) supplemented with 10 mM D-glucose (PBSG).
Following removal of

th~

plasma and buffy coat, the cells were resuspended (40%

hematocrit) and used the same day they were collected.

EPR studies

Reaction mixtures (2 ml) contained 10 mM EMPO, 0.1 mM DTPA in a red cell
suspension (40%) in PBSG at room temperature under aerobic conditions. Experiments
that utilized hemolyzed red cells were conducted by suspending wased red cells in icecold de-ionized water. Reactions were initiated by addition of MAQ-NOH dissolved in
DMSO (10 ttl). EPR spectra were recorded on a Bruker ELEXYS E-500-10/12
spectrometer system (Bruker Instruments, Inc., Billerica, MA) operating at 20 mW power
with a microwave frequency of 9.77 GHz, a receiver gain of 69, and a time constant of
0.164 sec.
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Stability of MAQ-NOH in buffer and in red cell suspensions was determined by
HPLC with electrochemical detection as described previously (Bolchoz et aI., 2001). For
experiments to determine the dependence of radical adduct generation on red cell GSH,
red cell suspensions were titrated with diethyl maleate to deplete aSH (by >95%) as
described previously (Bolchoz et aI., 2002).

Spectrophotometric detection of hemoglobin oxidation
Fonnation of methemoglobin was determined as described previously (Harrison and
Jollow, 1987; Bradshaw et aI., 1997). To determined if MAQ-NOH induced
ferrylhemoglobin formation in rat red cells (Harrison and Jollow, 1987; Bradshaw et aI.,
1997), aliquots (75 JlI) of MAQ-NOH-treated red cell suspensions were lysed in 5 ml of
hemolysis buffer (5 mM sodium phosphate dibasic, 0.5% triton X-laO, pH 7.5) and
analyzed in a Shimadzu UV-160A double-beam UV-visible spectrophotometer. The
amount of ferrylhemoglobin was measured in red cell incubates treated with sodium
sulfide (2 mM) at 37°C for 5 min prior to MAQ-NOH exposure. Sodium sulfide
irreversibly converts the unstable ferry I heme species to sulfhemoglobin which is
measured spectrophotometrically at 620 nm (Giulivi and Davies, 1990).

Results

Fonnation of EMPO radical adducts in rat red cells
To establish whether free radicals could be detected in rat red cells exposed to MAQNOH under previously determined hemolytic conditions (Bolchoz et aI., 2001), rat red
cell suspensions (400/0 hematocrit) containing 10. mM EMPO were exposed to 350 JIM
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MAQ-NOH. As shown in figure 4.1, a four line (1:2:2:1) EMPO radical adduct signal
was generated. The signal was dependent on the presence of MAQ-NOH (fig. 4.1B) and
EMPO (fig. 4.1C), and was generated equally well in intact and lysed red cells (fig. 4.1 A
and E). The nitrogen hyperfine splitting constants (Table 4.1) were identical to those of
an EMPO hydroxyl radical adduct (Olive et aI., 2000). As shown in figure 4.2, formation
of the EMPO-OH was concentration-dependent, and occurred over a range of hemolytic
concentrations of MAQ-NOH. No evidence for an EMPO-thiyl radical adduct or a
compound-centered free radical was observed in these incubates.

Time dependence of hydroxyl radical fonnation
Previous EPR studies using the spin trap, 5,5-dimethyl-pyrroline N-oxide (DMPO),
have demonstrated that glutathione thiyl radical adducts are generated in rat red cell
suspensions exposed to hemolytic concentrations of the arylhydroxylamine,
phenylhydroxylamine (Maples et aI., 1990; Bradshaw et aI., 1995). These experiments
also revealed that at higher drug concentrations and longer incubation times, the
glutathione thiyl radical adduct signal was replaced by a hemoglobin thiyl radical adduct
signal. In the present study, when rat red cells containing EMPO were exposed to MAQNOH (350 JlM) and the spectrum recorded for 30 min, no change in the shape of the
hydroxyl radical signal was detected (fig. 4.3). However, the signal intensity began to
decline after 20 min., due to decay.
To investigate whether the production of the hydroxyl radical was constant with time,
red cell suspensions were incubated with MAQ-NOH (350 JLM) and EMPO was added to
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A

B

c
D

Fig. 4.1. Detection of EMPO-radical adduct signal in rat erythrocytes exposed to MAQNOH. (A) EPR spectrum recorded 3 min after the addition of MAQ-NOH (350 /lM) to a
40% red cell suspension in PBSG containing 10 mM EMPO and 0.1 mM DTPA. (B) As
in A, except MAQ-NOH was omitted .. (C) As in A, except EMPO was omitted. CD) As in
A, except red cells were omitted. (E) As in A, except lysed red cells were used.
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Table 4.1. Hyperfine splitting constants of EMPO Hydroxyl Adduct Diastereomers

Spin Adduct
EMPO-OHa

EMPO-OHb

14.0

15.1

14.0

12.7

13.94

14.97

14.06

12.88

0.9

0.73

aFrom Olive, 2000
bSplitting constants determined from EPR spectrum shown in figure 4.1A.
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Fig. 4.2. Concentration-dependent increase in the MAQ-NOH-induced EMPO-OH signal
in rat erythrocytes. EPR spectrum recorded 3 min after the addition of (A) 150 JlM, (B)
350, (C) 750 JlM, or (D) 1.5 mM MAQ-NOH to 40% red cell suspension in PBSG
containing 10 mM EMPO and 0.1 roM DTPA.
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Fig. 4.3. Time dependence of MAQ-NOH-induced EMPO-radical adduct signal in rat
erythrocytes. EPR spectrum recorded (A) 1 min, (B) 3 min, (C) 6 min, (D) 10 min, (E) 15
min, and (F) 30 min after the addition of MAQ-NOH (350 JLM) to 40% red cell
suspension in PBSG containing 10 rnM EMPO and 0.1 rnM DTPA.
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Fig. 4.4. Effect of time of EMPO addition on the MAQ-NOH-induced EPR signal. 10mM EMPO was added to a 40% red cell suspension in PBSG containing 0.1 mM DTPA
(A) 1 min, (B) 5 min, (C) 10 min, (D) 20 min, (E) 30 min after the addition of MAQ·NOH (350 JlM). EPR spectrum recorded 3 min after the addition EMPO.
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the mixture after 1, 5, 10, 20, and 30 min. As seen in figure 4.4, the hydroxyl radical
adduct intensity was independent of the time the trap was added up to 20 min, after which
the signal intensity began to decline.
To determine the relative stability of MAQ-NOH in buffer (PBSG) vs. red cells, the
concentration of MAQ-NOH was measured in aliquots of the incubates by HPLC-EC. In
the presence of red cells at 37°C, MAQ-NOH was highly unstable and with a half-life of
about 2 min (data not shown). In contrast, when incubated in buffer alone, MAQ-NOH
was relatively stable, disappearing with a half-life of about 4 min.

Effect ofGSH depletion on hydroxyl radicalfonnation
Recent work in this laboratory has shown that MAQ-NOH hemolytic activity is
markedly enhanced in rat red cells depleted of reduced glutathione (>90%) (Bolchoz et
aI., 2002). To examine the effect of aSH depletion on hydroxyl radical fonnation, rat red
cells were depleted of GSH (>95%) by titration with diethyl maleate prior to their
exposure to MAQ-NOH. As shown in figure 4.5, hydroxyl radical adducts were not
detected in suspensions that lacked GSH, even using concentrations of MAQ-NOH as
high as 750 JlM.

Ferrylhemoglobinfonnation in rat red cells
Ferrylhemoglobin is known to be generated in red cells by the interaction of
oxyhemoglobin and H202, and is considered to be a potent cytotoxic oxidant capable of
peroxidation of unsaturated fatty acids (Kanner and Harel, 1985b; Kanner and Harel,
1985a; Galaris et aI., 1990). Since hemolytic concentrations of MAQ-NOH induce lipid
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Fig. 4.5. Effect of removal of GSH from rat erythrocytes on the MAQ-NOH generated
EPR signal. (A) EPR spectrum recorded 3 min after the addition of 150 JlM MAQ-NOH
to 40% red cell suspension in PBSG containing 10 mM EMPO and 0.1 mM DTPA. (B)
As in A, except red cells were treated with DEM to deplete aSH (>95%). (C) As in A,
except 750 J.LM MAQ-NOH was added. (D) As in C, except red cells were treated with
DEM to deplete GSH (>95%).
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peroxidation in rat red cells (Bolchoz et aI., 2002), it was of interest to determine if
ferrylhemoglobin was formed under the conditions used to detect free radical generation
by EPR. Spectrophotometric scans of rat red cells exposed to hemolytic concentrations of
MAQ-NOH (fig. 4.6) did not reveal the presence of ferrylhemoglobin as measured by
increased absorbance at 545 and 580 nm. However, when the rat red cells were pretreated
with Na2S to trap ferryl heme species as sulfuemoglobin (Berzofsky et aI., 1971), the
presence of ferrylhemoglobin could be demonstrated. The fact that ferrylhemoglobin was
detectable only by accumulation of sulfhemoglobin suggests a steady low level
production of this oxidant species during the incubation period. Production of ferry! heme
was dependent on MAQ-NOH

~oncentration

(fig. 4.7 A) and on incubation time (fig.

4.7B).

Effect ofGSH depletion onferrylheme and methemoglobinfonnation
Since the enhancement of MAQ-NOH hemolytic activity caused by depletion of
cellular GSH was accompanied by loss of the hydroxyl radical signal, it was of interest to
determine if the enhanced toxicity was accompanied by ferrylhemoglobin formation.
GSH-normal and GSH-depleted rat red cells were treated with a range of hemolytic
concentrations of MAQ-NOH and assayed for ferrylhemoglobin. As shown in figure

4.8A, depletion of cellular GSH prior to addition of MAQ-NOH had no effect of the
formation of ferryl heme in the red cells. Since ferrylhemoglobin is known to undergo a
comproportionation reaction with oxyhemoglobin to yield molecules of methemoglobin
(Giulivi and Davies, 1990), we also examined the effect of aSH depletion and of Na2S
pretreatment on MAQ-NOH-induced

methemo~lobin

levels. As shown in figure 4.8B,
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Fig. 4.6. Spectrophotometric detection of ferrylhemoglobin in rat erythrocytes exposed to
MAQ-NOH. Rat erythrocytes (40% suspension) were pre-incubated with sodium sulfide
(2 mM) to convert the ferryl heme species to sulfhemoglobin (Amax 620 nm) and then
exposed to 750 ILM MAQ-NOH for 30 min at 37°C. 10% Potassium cyanide (20 ILl) was
added to remove any absorbance interference due to methemoglobin.
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Fig. 4.7. Effect of concentration and time on MAQ-NOH-induced ferrylhemoglobin
formation. (A) Absorbance at 620 nm 10 min after the addition of various hemolytic
concentrations of MAQ-NOH to red cell incubates containing 2 mM sodium sulfide. 10%
Potassium cyanide (20 Jll) was added to remove any absorbance interference due to
methemoglobin. (B) As in A, except red cells were incubated in 350 jiM MAQ-NOH and
aliquots taken at various time points.
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Fig. 4.8. Effect of aSH depletion on MAQ . . NOH-induced (A) ferrylhemoglobin
formation. Absorbance was recorded at 620 nm 10 min after the addition of various
hemolytic concentrations of MAQ-NOH to red cell incubates containing 2 rnM sodium ·
sulfide. aSH-depleted red cells were treated with DEM prior to MAQ-NOH exposure.
10% Potassium cyanide (20 Jll) was added to remove any absorbance interference due to
methemoglobin. Data points are means + SD (n=6). (B) As in A, except methemoglobin
was determined as described previously (Harrison and Jollow, 1987). Data points are
means + SD (n=4).
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depletion of GSH from the rat red cells also had no effect on the formation of
methemoglobin.
Since inclusion of Na2S in the incubation medium acts to trap ferryl heme as it is
formed, comparison of methemoglobin levels in the presence and absence of Na2S is a
measure of the contribution of this pathway to methemoglobin formation induced by
MAQ-NOH. As shown in figure 4.9, methemoglobin formation was unaffected by the
presence of Na2S, indicating that ferryl heme is not a major contributor to MAQ-NOHinduced methemoglobin fonnation.

Discussion
In previous studies on primaquine-induced hemolytic anemia, we demonstrated that
its N-hydroxy metabolit.e, MAQ-NOH, is directly hemolytic in rats and that this
hemotoxicity is associated with lipid peroxidation without significant protein oxidation
(Bolchoz et aI., 2001, Bolchoz, 2002 #306). However, when GSH is depleted prior to
MAQ-NOH exposure, there is a pronounced exacerbation of MAQ-NOH hemolytic
activity, and this exacerbation is accompanied by the appearance of protein oxidation
without change in lipid peroxidation. The present studies were undertaken to determine if
radical species are produced in rat red cells exposed to hemolytic concentrations of
MAQ-NOH, and if so, whether the enhancement of hemolytic activity by aSH depletion
is accompanied by alterations in free radical formation.
Experimentally, rat red cells were incubated with MAQ-NOH and analyzed by EPR
using EMPO as the free radical spin trap. EMPO was utilized instead of the more widely
used trapping agent, DMPO, because its superoxide radical adduct is more stable and
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Fig. 4.9. Effect of Na2S pretreatment on MAQ-NOH-induced methemoglobin formation.
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does not spontaneously decay to a hydroxyl radical adduct signal (Olive et aI., 2000;
Zhang et aI., 2000), as is observed with the DMPO-superoxide adduct (Thomalley, 1986;
Makino et aI., 1990; Hanna et aI., 1992). We report that MAQ-NOH generated an
EMPO-hydroxyl radical adduct (fig 4.1) that was dependent on the presence of red cells
(intact or lysed), EMPO, and MAQ-NOH. The EMPO-hydroxyl radical adduct signal was
stable for 20 min (fig. 4.3) and its intensity was proportional to MAQ-NOH concentration
(fig. 4.2). Addition of the EMPO reagent at intervals after exposure of the red cells to
MAQ-NOH (fig. 4.4) generated a radical signal at a constant intensity for at least 20 min.
As noted above, depletion of red cell aSH prior to the addition of MAQ-NOH
significantly enhances the hemolytic activity of MAQ-NOH. Paradoxically, hydroxyl
radical was not only not enhanced, but was lost completely (fig. 4.5). Furthennore, the
increased toxicity was not accompanied by an increase in ferryl heme formation (fig.
4.8A), and, hence by implication, not by increased levels of hydrogen peroxide.
Although a hydroxyl radical has previously been shown to be generated in red cells
exposed to other hemolytic N-hydroxylamines, such dapsone hydroxylamine (Bradshaw
et aI., 1997), the mechanism by which the radical is generated is unclear. It is well known
that oxyhemoglobin exists in the red cell as an equilibrium mixture, which includes a
superoxide-ferriheme component. Dissociation of this complex is believed to be
responsible for the constant, low-level oxidant stress that is present in unchallenged red
cells. Kiese and colleagues (for review, see Kiese, 1974) proposed an interaction between
arylhydroxylamines and oxyhemoglobin that may be regarded as an exacerbation of this
normal process. Thus, they described the occurrence of a cyclic oxidation-reduction
reaction between arylhydroxylamines and oxyhemoglobin, that yields the nitrosoarene,
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methemoglobin, and a reactive oxygen specIes (such as superoxide or hydrogen
peroxide), respectively. Subsequent reduction of methemoglobin by NADH-dependent
methemoglobin reductase, and of the nitrosoarene by a NADPH-dependent diaphorase,
would support a greater than one-to-one stoichiometry in regard to acti ve oxygen
production. Superoxide/hydrogen peroxide would in turn generate hydroxyl radicals by
way of an iron-catalyzed Fenton reaction. Although there is controversy over whether
hemoglobin is able to catalyze a Fenton reaction (Gutteridge, 1986; Puppo and Halliwell,

1988; Dong Mao et aI., 1994), Comporti and colleagues (Ferrali et aI., 1992; Ciccoli et
aI., 1994; Ciccoli et aI., 1999) have presented evidence to suggest that oxidation of
hemoglobin to methemoglobin facilitates the release of heme and/or free iron in a
diffusible, redox-active form.
Although the MAQ-NOH-induced hydroxyl radical of the present studies could be
generated by this mechanism, the loss of the hydroxyl radical when aSH was depleted
from the red cells strongly suggests that GSH is involved in the process. An alternate
hypothesis, proposed by Winterbourn and colleagues (Munday and Winterbourn, 1989;
Winterbourn, 1993), is that superoxide formation is dependent on GSH. In this concept,
GSH acts as a direct radical scavenger of a di verse range of radical species, accepting the
unpaired electron from the radical to form a glutathione thiyl radical intennediate. The
thiyl radical electron is then passed on to molecular oxygen to form superoxide anion
radical, which under normal conditions is detoxified by superoxide dismutase, creating a
GSHlsuperoxide radical sink. In the present studies, an excessive production of
superoxide/hydrogen peroxide induced by the hemolytic concentration of MAQ-NOH, in
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the presence of kinetically-free iron derived from methemoglobin, could account for the
observed hydroxyl radical signal.
It is apparent that while the GSHIsuperoxide radical sink concept explains
satisfactorily the dependence of the hydroxyl radical signal on cellular aSH levels, it
does not provide an explanation for the initiation of the radical series or how
methemoglobin formation is provoked by MAQ-NOH. The relative stability of MAQNOH in buffer (T1I2 ca. 4 min) as compared with its instability in the red cells (Tl/2 < 2
min) suggests that a spontaneous reaction with molecular oxygen (i.e., auto-oxidation) to
generate the initial radical species is unlikely, and that in some fashion, hemoglobin or
other cellular constituents are needed to initiate radical formation. Similarly, comparison
of methemoglobin levels in the presence and absence of Na2S (fig. 4.9) indicates that the
comproportionation of ferryl heme is not a major contributor to MAQ-NOH-induced
methemoglobin formation, and hence that methemoglobin must arise by a different
pathway.
While neither postulate alone provides a' satisfactory explanation, a combination
appears to be compatible with the current data. Thus, the very rapid disappearance of
MAQ-NOH in red cells and rapid formation of methemoglobin (Bolchoz et aI., 2001)
suggest that the interaction of MAQ-NOH and hemoglobin could gene-rate
methemoglobin and a compound-centered free radical, such as a quinoline hydronitroxide
radical. The generation of this species

ma~

be analogous to the formation of the

phenylhydronitroxide radical form of phenylhydroxylamine described by Mason and:
colleagues (Maples et aI., 1990). Once formed, the nitroxide free radical could react with
aSH to form a thiyl radical, which in tum, could generate a superoxide radical and lead
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to hydrogen peroxide formation

vi~

superoxide dismutase (Fridovich, 1975). As noted

above, kinetically-free iron derived from methemoglobin could catalyze hydroxyl radical
formation.
Although this combined schema permits rationalization of the available data, it should
be noted that there are major discrepancies. First, we have been unable to detect a
compound-centered radical derived from MAQ-NOH in the red cell incubates. Of
interest, aerobic incubation of MAQ-NOH in PBSG buffer alone (without the iron
chelator, DTPA) gives rise to a radical species that can be detected by EPR (data not
shown). The identity of this species and its relevance to hemotoxicity are currently under
investigation. Second,

w~

have been unable to clearly detect a glutathione thiyl radical in

MAQ-NOH incubates. This is of concern since previous analogous studies with
phenylhyrdroxylamine demonstrated the presence of thiyl radicals (Maples et aI., 1990;
Bradshaw et aI., 1995). However, since the EMPO-hydroxyl and EMPO-GSH thiyl
radical adduct signals are similar, with a characteristic 1:2:2: 1 signal pattern, simulation
experiments are necessary to determine if this signal is present and just masked by the
hydroxyl signal.
A third major concern is the lack of correlation between the very rapid disappearance
of MAQ-NOH and the apparent steady production of hydroxyl radical for at least 20 min
after addition of the MAQ-NOH to the red cells. The fact that hydroxyl radical continues
to be generated long after MAQ-NOH has disappeared argues strongly that MAQ-NOH
induces the fonnation of an as yet undetected, more stable intermediate. Support for the
existence of such a species can also be seen in MAQ-NOH-treated, GSH-depleted red
cells. Although the hydroxyl radical can no longer be detected, addition of the lipid
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soluble sulfhydryl-donating compound, cysteamine, leads to the trapping of a cysteamine
thiyl radical by EMPO (Bolchoz et aI., unpublished observations). Thus even in red cells>
in which the hydroxyl radical is not detectable, a precursor species more stable that
MAQ-NOH must be present.
The role of hydrogen peroxide in the hemolytic process is also unclear. It is well
known that hydrogen peroxide reacts with hemoglobin to form ferryl heme and hence
that ferryl heme levels in the red cells reflect the generation of hydrogen peroxide in
excess of its metabolic clearance (Kanner and Harel, 1985b;. Kanner and Harel; 1985a;
Harel and Kanner, 1988). Thus the formation of ferrylhemoglobin in these red cells may
be taken as evidence for the formation of excess hydrogen peroxide under MAQ-NOHinduced hemolytic conditions. However, it has long been thought that glutathione
peroxidase plays a major role in the removal of hydrogen peroxide from the red cell
(Jacob, 1965). Thus, in the present studies, depletion of GSH from the red cells should
have decreased hydrogen peroxide elimination by glutathione peroxidase, resulting in
enhanced hydrogen peroxide levels and enhanced ferryl heme formation. Experimentally,
depletion of red cell GSH had no effect on the production of ferryl heme (fig. 4.8A),
implying no significant change in hydrogen peroxide levels. Since ferryl heme appears to
play little or no role in MAQ-NOH-induced methemoglobin formation (fig. 4.8B), the
lack of enhancement in ferryl heme levels is not due to enhanced removal by
comproportionation to methemoglobin. The data are consistent with the proposal by
Eaton and colleagues (Eaton, 1991) that catalase plays a more significant role in
controlling red cell peroxide levels than has previously been considered.
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In summary, the present studies clearly demonstrate that under hemolytic conditions,
MAQ-NOH generates three active oxygen species in rat red cells: hydroxyl radical,
hydrogen peroxide and ferryl heme, each of which has the chemical potential to inflict
the initial oxidant injury to the red cell that ultimately leads to its premature sequestration
by the spleen. However, enhancement of the susceptibility of the cells by prior depletion
of cellular GSH did not increase the levels of any of these species and hence these data
alone do not allow us to conclude which, if any, of these oxidants could be causal in
MAQ-NOH hemotoxicity. Of particular interest, the marked discrepancy between the
rapid disappearance of MAQ-NOH from the red cell incubate and the sustained oxidant
stress for at least 20 min suggests the presence of an, as yet, undetected pro-oxidant
species derived from MAQ-NOH under hemolytic conditions.

CHAPTERS
Summary
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Summary
Hemolytic anemia has been recognized as a toxic side effect of a wide variety of
drugs and environmental chemicals for more than 50 years (Cordes, 1926). While the
precise mechanism in which these agents elicit a hemolytic response remains unclear, it is
generally accepted that oxidative stress plays a central role. Support for the oxidative
stress concept lies in a number of observations made in early mechanistic studies (for
review, see Beutler, 1959). These include: 1) loss of cellular reduced glutathione
following exposure to these agents, 2) oxidation of oxyhemoglobin to methemoglobin,
and 3)- cells that are unable to maintain adequate levels of the reductant NADPH (i.e.,
G6PD deficient cells) when faced with an oxidative challenge are the most sensitive to
these agents. In addition, these studies established that metabolites were responsible for
the hemolytic activity of the parent compound.
While the crucial role for metabolism in primaquine-induced hemolytic anemia is
well accepted, the hemotoxic metabolite(s) have not been identified. Furthermore, the
mechanism underlying this toxicity is not fully understood. This is in one part due to
multiple oxidation sites on the primaquine molecule that give rise to a number of possible
primary metabolites that may be further metabolized. Secondly, many of these putative
metabolites are known to be chemically unstable in biological systems (Strother et aI.,
1981; Idowu et aI., 1995). In addition, investigators lack a good primaquine-sensitive
experimental animal model (Lee et aI., 1981).
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It has long been suggested that primaquine hemotoxicity is mediated by redox active
phenolic metabolites of the parent compound (Tarlov et aI., 1962). These metabolites are
believed to redox cycle within the red cell to their respective quinone/ quinoneimine
structure resulting in the formation of reactive oxygen species (Link et aI., 1985). In
support, 5-0H-PQ and 5,6-DHPQ have been detected in the biological fluid of
experimental animals administered primaquine (Strotheret aI., 1981; Strother et aI.,
1984; Idowu et ai., 1995), and these metabolites have been shown to decrease
erythrocytic GSH levels and oxidize hemoglobin to methemoglobin in both normal and
G6PD-defecient erythrocytes (Fraser and VeseIl, 1968; Agarwal et aI., 1988; 'Fletcher et
aI., 1988). However, these derivatives have not been detected in humans (Baty et aI.,
1975; Mihaly et aI., 1984).
Alternatively, previous studies with hemolytic arylamines such as aniline (Harrison
and Jollow, 1986), phenacetin (Jensen and Jollow, 1991), and dapsone (Grossman and
Jollow, 1988), have shown that their N-hydroxy metabolites are the hemotoxic species.
Evidence suggests that these agents evoke an oxidative stress within the red cell through
a cyclic oxidation-reduction reaction that occurs between the arylhydroxylamine,
oxyhemoglobin, and molecular oxygen yielding the nitrosoarene, methemoglobin, and
partially reduced forms of oxygen, respectively (Rostorfer and Cormier, 1957; Kiese,
1974). In support, extensive studies on the mechanism of DDS-NOR-induced hemolytic
anemia revealed that this metabolite induced a variety of oxidative events in rat and
human erythrocytes under hemolytic 'conditions (Grossman and Jollow, 1988; Grossman
et aI., 1992; McMillan et aI., 1995; Bradshaw et aI., 1997). These include: 1) rapid and
extensive depletion of GSH with a concomitant formation of GSH-protein mixed
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disulfides, 2) formation of disulfide-linked hemoglobin adducts to certain membrane
skeletal proteins, 3) oxidation of hemoglobin, and 4) generation of hydroxy I radicals. In
contrast, DDS-NOH did not oxidatively damage red cell membrane lipids (McMillan et
aI., 1998). Collecti vely, these observations led to the concept (fig. 1.5) that
ary Ihydroxy lamines redox cycle within the red cell, generating oxygen-centered free
radicals, which in tum form aSH and hemoglobin thiyl radicals. The hemoglobin thiyl
radicals are believed to further react with the sulfhydryl groups of the membrane skeletal
proteins to fonn hemoglobin-skeletal protein adducts and ultimately mark the red cell for
premature removal by the spleen (Grossman et aI., 1992).
In light of these studies, this dissertation examines the possible role of an N-hydroxy
metabolite in primaquine-induced hemotoxicity. The experimental approach was to
determine if this type of metabolite is formed metabolically, to establish its hemolytic
acti vi ty, to characterize the pattern of oxidative damage induced in the red cell
particularly to membrane lipids and cytoskeletal proteins and to identify the nature of the
oxidati ve stress generated by this metabolite in the red cell.

Fonnation and hemotoxicity o/primaquine N-hydroxy metabolite
As 6-methoxy-8-aminoquinoline (6-MAQ) is one of two known human primaquine
metabolites, rat and human microsomes were analyzed for their capacity to Nhydroxylate this metabolite. As seen in figure 2.5, incubation of 6-MAQ with rat and
human liver microsomes resulted in the formation of a single metabolite that was
identified by mass spectrometry to be MAQ-NOH (fig. 2.7). MAQ-NOH was further
shown to be hemolytic in vivo as measured by the decreased survival of S 1er-Iabeled
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erythrocytes in rats. Of particular interest, incubation of MAQ-NOH with 51Cr-labeled
erythrocytes in vitro resulted in a concentration-dependent increase (ECSO 350 JiM) in
their rate of removal when administered to a group of isologous rats. MAQ-NOH also
induced a concentration-dependent increase in methemoglobin levels in rat red cells
when exposed in vitro. Collectively these data suggest that the 6-MAQ can be
metabolized to MAQ-NOH and that this metabolite has the requisite properties to playa
role in the hemolytic activity of primaquine. However, the contribution of MAQ-NOH to
primaquine-induced hemolytic anemia in vivo remains to be assessed.

Hemolytic

d~se-respose·relationship

In regard to the in vitro exposure/ in vivo survival assay employed in this aim, it is
important to note that the metabolite concentrations needed to elicit a hemolytic response
in vitro may not be extrapolated to define the concentration of these drugs needed to elicit

a hemolytic response in vivo. One reason for this is that the hemolytic activity of these
agents is being tested in G6PD-normal rat erythrocytes. Since these red cells have normal
aSH levels and can maintain NADPH levels and hence antioxidant enzyme activity when

challenged with an oxidative stress, we must use metabolite concentrations that not only
deplete aSH, but also generate enough oxidative stress to overwhelm the antioxidant
enzymes in order to elicit a toxic response.
Secondly, drug-induced hemolytic

ane~ia

is believed to be the result of an

accumulation of multiple "hits" after which a threshold is reached the cells are removed
from circulation. Thus hemolytic damage would be proportional to the area under the
metabolite plasma concentration vs time curve and not the peak metabolite plasma levels,
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as has been illustrated for the hemolytic metabolite of dapsone, dapsone hydroxylamine
(Grossman and Jollow, 1988). Primaquine has a half-life of about 6 hrs (Mihaly et al.,
1984), therefore it is conceivable that 6-MAQ and MAQ-NOH will be produced at a low

but steady rate. Since primaquine is usually administered chronically, the area under the
MAQ-NOH plasma concentration versus time curve may be significant, particularly in a
G6PD-deficient individuaL However, since the red cells in our survival assay are only
exposed to the metabolites in vitro for 2 hrs, higher than physiological relevant
concentrations of metabolites must be used.
On the contrary, this assay does provide a method in which shorter incubation times
can be used to determine the relative potencies of direct acting hemolytic

compounds~

In

addition, in vitro experimental conditions are established that result in the in vivo
premature sequestration of red cells. Thus parallel studies may be conducted to examine
the biochemical changes that occur in the red cells under these conditions and their
possible role in marking the red cell for removal ascertained.

Oxidative effects of MAQ-NOH in rat erythrocytes under hemolytic conditions

Being that MAQ-NOH is an arylhydroxylamine like

DDS~NOH,

it was expected to

behave in a similar nature in the red blood cell. However, in marked contrast to the DDSNOH, MAQ-NOH was shown to induce significant lipid peroxidation in rat erythrocytes
with little effect on the membrane skeletal proteins under equally hemolytic conditions.
Of particular interest, MAQ-NOH exposure resulted in hemoglobin monomer association
with the erythrocyte lipid membrane. The monomer could not be removed despite
multiple rigorous washes in phosphate buffer suggesting it was bound either non-
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covalently (hydrophobic interactions) or covalently to the lipid bilayer. As this monomer
has also been seen in red cells treated with other hemolytic agents, for example DDSNOH, phenylhydrazine, and divicine, the nature of the monomer association with the red
cell membrane and its possible role in marking the cell for splenic sequestration as
apposed to or in conjunction with the cytoskeletal adducts or lipid peroxidation becomes
of interest.
MAQ-NOH was also shown to differ from DDS-NOH in its effects on aSH in rat red
cells. As illustrated in figure 3.1, MAQ-NOH only moderately and transiently decreased
aSH levels. In fact the concentration-response curve for MAQ-NOH aSH depletion is

far to the right of its hemolytic response curve suggesting that GSH depletion is not a
prerequisite for oxidative hemolytic damage.

Oxidative effects of MAQ-NOH in GSH-depleted rat erythrocytes

In an effort to investigate the oxidative effects of MAQ-NOH on red cells that more
closely resemble G6PD deficient red cells (i.e. cells with reduced levels of GSH (Beutler,
1978), rat red cells were treated with OEM to deplete GSH prior to exposure to hemolytic
concentrations of MAQ-NOH. As seen in figure 3.5, GSH depletion markedly enhanced
MAQ-NOH hemolytic activity as expected. However, the increase in toxicity was not
accompanied by an increase in lipid peroxidation. Surprisingly, MAQ-NOH induced a
concentration-dependent increase in membrane skeletal protein hemoglobin adducts in
red cells absent of aSH. Collectively these data suggest that MAQ-NOH may mediate its
hemolytic activity through more than one mechanism; one that involves lipid
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peroxidation in red cells with notmal levels of GSH and protein oxidation in red, cells
with decreased aSH levels, such as those seen in G6PD-deficient individuals.

DEM-treated erythrocytes as a model ofG6PD deficiency
Although DEM-treated red cells are more sensitive to oxidative injury, there are some
differences between these cells and G6PD-deficient cells. First, GSH levels are known to
be decreased in G6PD-deficient cells (Beutler, 1978), however in red cells exposed to
DEM, aSH is essentially absent. Though DEM-treated red cells may represent G6PD
cells following an oxidative stress. Secondly, DEM does not specifically react with GSH.
Sulfhydryl groups on cellular proteins may also be blocked by DEM. In an effort to
minimize this possibility, red cell GSH is titrated out with small aliquots of DEM.
Furthermore, should any DEM side reactions be occurring in our experiments, this does
not appear to effect the in vivo survival, levels of lipid peroxidation, or protein
electrophoretic pattern of these red cells as indicated in control experiments.
It is also important to note that a more specific method than DEM treatment does
exits in which to model G6PD deficiency. This approach involves the use of steroids such
as epiandrosterone to non-competitively inhibit G6PD (Marks and Banks, 1960). Our
laboratory has previously employed this technique to demonstrate an enhanced sensitivity
of G6PD inhibited rat red cells versus uninhibited cells to DDS-NOH (Grossman et aI.,
1995). The difference in sensitivity in these experiments was comparable to that seen by
Degowin et al. in G6PD-deficient and normal individuals given dapsone (Degowin et al.,
1966). However, despite multiple attempts, we have been unable to successfully inhibit
G6PD to the extent necessary to represent an A- G6PD deficient individual (>950/0
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inhibition) since these studies. Efforts to elucidate the reason for this lack of response are
being continued.

Effect of MAQ-NOH on free radical formation in rat erythrocytes
In light of the critical role of oxidative stress in drug-induced hemolytic anemia,
additional experiments were conducted to detect and identify any free radicals generated
in rat red cells exposed to hemolytic concentrations of MAQ-NOH. EPR analysis using
the spin trap 2-ethoxycarbonyl-2-methyl-3,4-dihydro-2H-pyrrole-l-oxide (EMPO)
revealed that in normal rat red cells, MAQ-NOH generated a hydroxyl radical adduct
signal in a concentration-dependent manner. Surprisingly, this radical was continuously
generated for up to 20 min despite that MAQ-NOH has a half-life of less than a minute in
blood (Bolchoz et. aI., unpublished data). Furthermore, in conjunction with the above
studies, red cells treated with DEM to deplete GSH prior to MAQ-NOH exposure were
also examined by EPR. Interestingly, no radical adduct signal was detected under these
conditions in rat red cells suggesting that MAQ-NOH-induced hydroxyl radical formation
was GSH dependent. Of particular importance, these data raise the possibility that a third
type of radical (i.e. compound-centered radical) may be initially generated in response to
MAQ-NOH that reacts with GSH to ultimately give rise to a hydroxyl radical. This
radical may also be more cytotoxic than the hydroxyl radical as MAQ-NOH hemolytic
activity is known to be markedly enhanced in aSH-depleted red cells. Additional
spectrophotometric analysis of MAQ-NOH treated red cells revealed the presence of
ferrylhemoglobin, thereby confirming the presence of hydrogen peroxide and by
inference superoxide in these cells. The role of ferryl heme species in MAQ-NOH

120
hemolytic activity remains to be determined. In addition, whether a compound-centered
radical is produced in red cells in response to MAQ-NOH and its role in causing the
intracellular lesions described above certainly warrants further investigation.
Conclusion

In trying to answer the question of which primaquine metabolite mediates its
hemotoxic side effects, the first phase of this project was to determine if the known

human primaquine metabolite 6-MAQ could be N-hydroxylated to MAQ-NOH. Evidence
is presented to show that MAQ-NOH is not only formed from 6-MAQ, but that it is
directly hemotoxic. MAQ-NOH was further demonstrated to be hemolytic in vivo.
Despite that this metabolite has

~he

requisite properties to mediate parent compound

hemolytic anemia, its relative contribution remains unclear. This is largely due to the
possible contribution of the redox active phenolic metabolites to the toxicity. In this
regard, preliminary studies in our laboratory have demonstrated that the phenolic
metabolites of primaquine are also directly hemolytic (fig 5.1). In fact these metabolites
appear to be markedly more potent than MAQ-NOH in normal rat erythrocytes.
However, there exists no evidence to support that these metabolites are formed in
humans. Furthermore, should these metabolites be produced in vivo, the possibility exists
that they may never reach the circulation to mediate this toxicity due to their extreme
chemical instability or further metabolism. In support, 2-aminophenol and 4aminophenol, the phenolic metabolites of

anil~ne,

although directly hemotoxic, were

found to be rapidly eliminated by hepatic conjugation and not to contribute to the parent
compound hemotoxicity (Harrison and Jollow, 1986; Harrison and JoHow, 1987). Studies
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Fig. 5.1. Survival of rat 51Cr-Iabeled erythrocytes in vivo after in vitro exposure to the
phenolic metabolites of primaquine 5HQ, 5-hydroxy-6-methoxy-8-aminoquinoline,
5HPQ, 5-hydroxyprimaquine, and 5,6DHPQ, 5,6-dihydroxyprimaquine. The red cells
were incubated with the phenolic metabolites for 2 hr at 37°C; control cells were
incubated with vehicle (PBSG) alone. The erythrocytes were then washed and
administered i. v .. to isologous rats. To blood samples were taken 30 min after
administration of the labeled cells. Data points are means + SD (n=4).
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In summary, while it is difficult to speculate on the molecular mechanism
NOH-induced hemolytic activity at this point, these data
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Fig. 5.2. The effect of cysteamine on the survival of rat 51Cr-labeled erythrocytes in vivo
after in vitro exposure to (A) DDS-NOH (180 JlM) or (B) MAQ-NOH (450 JlM). The red
cells were incubated with 5 mM cysteamine and either DDS-NOH or MAQ-NOH for 2 hr
at 37°C; control cells were incubated with vehicle (FBSG) alone. The erythrocytes were
then washed and administered i.v. to isologous rats. To blood samples were taken 30 min
after administration of the labeled cells. Data points are means + SD (n=4).
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Fig. 5.3. The effect of cysteamine on the survival of GSH-depleted 51 Cr-labeled rat
erythrocytes in vivo after in vitro exposure to MAQ-NOH (250 ILM). Rat red cells were
depleted of GSH (>90%) using DEM an.d incubated with either MAQ-NOH alone or 5
mM cysteamine and MAQ-NOH for 2 hr at 37°C; control cells were incubated with
vehicle (20 ILl DMSO) alone. The erythrocytes were then washed and administered i.v. to
isologous rats. To blood samples were taken 30 min after administration of the labeled
cells. Data points are means + SD (n=4).
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